University of the Pacific

Scholarly Commons
University of the Pacific Theses and
Dissertations

Graduate School

1981

Differentiation of dopamine receptor types in the central nervous
system of the rat
Ihor Krewsun
University of the Pacific

Follow this and additional works at: https://scholarlycommons.pacific.edu/uop_etds
Part of the Life Sciences Commons, and the Physical Sciences and Mathematics Commons

Recommended Citation
Krewsun, Ihor. (1981). Differentiation of dopamine receptor types in the central nervous system of the rat.
University of the Pacific, Thesis. https://scholarlycommons.pacific.edu/uop_etds/2063

This Thesis is brought to you for free and open access by the Graduate School at Scholarly Commons. It has been
accepted for inclusion in University of the Pacific Theses and Dissertations by an authorized administrator of
Scholarly Commons. For more information, please contact mgibney@pacific.edu.

DIFFERENTIATION OF DOPAMINE RECEPTOR TYPES
IN THE CENTRAL NERVOUS SYSTEM

OF THE RAT

A Thesis
Presented to
the Faculty of the Graduate School
University of the Pacific

In Partial Fulfillment

.

of the Requirements for the Degree
Master of Science

by
Ihor Krewsun
December 1981

ACKNOWLEDGMENTS
The author wishes to express sincere thanks to Drs.
Raymond Quack, David Fries, Katherine Knapp, James Blankenship, and

Ma~vin

Malone for their skillful instruction

and generous gifts of knowledge and experience in the preparation of. this thesis; his parents, for their unending
love and support; and his lifelong colleague and friend,
Dr. Paul Culver, whose constant encouragement has been
most valuable.
The author wishes to express additional thanks to the
following:
John Martin, Mark Berman, Ron Wade, John Byrne, John
Taylor and Carl Schweitzer for their valuable assistance
in the laboratory.
John McCormick; Juan Echeguren, Monte Guadagnolo,
Gary Guadagnolo and Tom Rose, whose multifaceted view of
life has helped me integrate science, art and music.

ii

TABLE OF CONTENTS
Page
LIST OF TABLES.

iv

LIST OF FIGURES

vi

LIST OF PLATES.

xi

INTRODUCTION.

.

l

LITERATURE SURVEY

3

Dopaminergic Systems in the Central Nervous
System. . . . . . .
. . . . . . . . .

3

Dopaminergic Involvement in the Control of
Locomotor Activity in Rats . . . . . . . .

7

Dopaminergic Involvement in Apomorphine-Induced
Stereotyped Behavior. . . . . . . . . . . . . .

10

Dopaminergic Involvement in Neuroleptic-Induced
Catalepsy . . . . . . . . . . . . . . . . . . .

13

Dopaminergic Involvement 0f Apomorphine-Induced
Hypothermia in Rat. . . . . . . . . . . . .

19

Evidence to Suggest Multiplicity of Dopamine
Receptors in the Central Nervous System

22

STATEMENT OF THE PROBLEM.

32

MATERIALS AND METHODS

34

RESULTS .

47

DISCUSSION.

110

CONCLUSIONS

124

REFERENCES.

126

iii

LIST OF TABLES
Table

I.
II.

III.

IV.

v.

VI.

Page
Scoring System for Estimation of the Intensity of Stereotyped Behavior . . . . . . .

41

The effect of pretreatment (-30 minutes)
with either haloperidol lactate, lenperone
hydrochloride, chlorpromazine hydrochloride
or thioridazine hydrochloride on the locomotor activity effects of intraperitoneal
apomorphine hydrochloride over a 60-minute
period in male rats. . . .
. ....

48

The effect of pretreatment (-30 minutes)
with either haloperidol lactate, lenperone
hydrochloride, chlorpromazine hydrochloride
or thioridazine hydrochloride on stereotyped behavior produced by intraperitoneal
apomorphine hydrochloride over a 90-minute
period in male rats . . . . . . . . . . .

60

The effect of treatment with either haloperidol lactate, lenperone hydrochloride,
chlorpromazine hydrochloride or thioridazine hydrochloride on the ability of male
rats to maintain a cataleptic position
over a 90-minute testing period . . . .

69

The effect of pretreatment (-30 minutes)
with either haloperidol lactate, lenperone
hydrochloride, chlorpromazine hydrochloride
or thioridazine hydrochloride on the rectal
temperature effects of intraperitoneal
apomorphine hydrochloride over a 90-minute
testing period in male rats . . . . . . . .

79

The ED5o and mole ED 50 of haloperidol lactate on its ability to block apomorphine
hydrochloride-induced effects and to induce
catalepsy . . . . . . . . . . . . . . . . .

92

iv

LIST OF TABLES
(continued)

Table

VII.

VIII.

IX.

X.

XI.

Page
The EDso and mole EDso of lenperone hydrochloride on its ability to block apomorphine hydrochloride-induced effects and
to induce catalepsy . . . . . . . . . . .

93

The EDso and mole ED 50 of chlorpromazine
hydrochloride on its ability to block
apomorphine hydrochloride-induced effects
and induce catalepsy . . . . . . . . .

94

The EDso and mole EDso of thioridazine
hydrochloride on its ability to block
apomorphine hydrochloride-induced effects
and to induce catalepsy . . . . . . . . . .

95

Regression analysis of the logarithm of the
molar EDso of haloperidol lactate, lenperone hydrochloride, chlorpromazine hydrochloride and thioridazine hydrochloride in
a series of four pharmacological parameters;
body temperature, stereotyped behavior,
locomotor activity and catalepsy . . . . . .

96

Regression analysis of the logarithm of the
molar EDso of haloperidol lactate, lenperone hydrochloride and chlorpromazine
hydrochloride (excluding thioridazine hydrochloride in this analysis) in a series of
four pharmacological parameters; body temperature, stereotyped behavior, locomotor
activity and catalepsy . . . . . . . . . .

97

v

LIST OF FIGURES
Figure

Page

1.

Major dopaminergic pathways . . . .

2.

Structural formulas of dopamine and the
dopamine agonist, apomorphine.

35

Structural· formulas of two butyrophenones,
haloperidol and lenperone . . . . .

36

Structural formulas of two phenothiazines,
chlorpromazine and thioridazine . . .

37

The mean effects of intraperitoneal apomorphine hydrochloride or double-distilled
water on the locomotor activity of male
rats pretreated (-30 minutes) with doubledistilled water.

49

The mean effects of pretreatment (-30
minutes) with haloperidol lactate on the
locomotor activity effects of intraperitoneal apomorphine hydrochloride administered to male rats . . . . . .

51

The mean effects of pretreatment (-30
minutes) with lenperone hydrochloride on
the locomotor activity effects of intraperitoneal apomorphine hydrochlor.ide
adriliriistered to male rats .
. . .

53

The mean effects of pretreatment (-30
minutes) with chlorpromazine hydrochloride
on the locomotor activity effects of intraperitoneal apomorphine hydrochloride administered to male rats .

55

The mean effects of pretreatment (-30
minutes) with thioridazine hydrochloride
on the locomotor activity effects of intraperitoneal apomorphine hydrochloride
administered to male· rats.

57

3.
4.
5.

6.

7.

8.

9.

vi

4

LIST OF FIGURES
(continued)
Figure
10.

11

12.

13.

14.

15.

16.

17.

18.

Page
The mean effects of pretreatment (-30
minutes) with haloperidol lactate on
stereotyped behavior produced by intraperitoneal apomorphine hydrochloride
administered to male rats.

61

The mean effects of pretreatment (-30
minutes with lenperone hydrochloride
on stereotyped behavior produced by intraperitoneal apomorphine hydrochloride administered to male rats . .

63

The mean effects of pretreatment (-30
minutes) with chlorpromazine hydrochloride
on stereotyped behavior produced by intraperitoneal apomorphine hydrochloride administered to male rats.

65

The mean effects of pretreatment (-30
minutes) with thioridazine hydrochloride
on stereotyped behavior produced by intraperitoneal apomorphine hydrochloride administered to male rats . . . . . .

67

The mean effects of treatment with haloperidol lactate on the ability of male
rats to maintain a cataleptic position .

70

The mean effects of treatment with lenperone hydrochloride on the ability of male
rats to maintain a cataleptic position

72

The mean effects of treatment with
chlorpromazine hydrochloride on the ability
of male rats to maintain a cataleptic
posit ion
. . .
. . . .

74

The mean effects of treatment with thioridazine hydrochloride on the ability of
male rats to maintain a cataleptic position . .
. . . . . . . . .

76

The mean effects of intraperitoneal haloperidol lactate, lenperone hydrochloride,
chlorpromazine hydrochloride or thioridazine hydrochloride on the rectal temperature of male rats.
. ....... .

80

vii

LIST OF FIGURES
(continued)
Figure
19.

20.

21.

22.

23.

24.

Page
The mean effects of pretreatment (-30 minutes) with haloperidol lactate on the body
temperature effects of intraperitoneal
apomorphine hydrochloride administered to
male rats . . . . . . . . . . . . . . .

82

The mean effects of pretreatment (-30 minutes) with lenperone hydrochloride on the
body temperature effects of intraperitoneal
apomorphine hydrochloride administered to
male rats. .
. . . . . . . .
. ..

84

The mean effects of pretreatment (-30 minutes) with chlorpromazine hydrochloride on
the body temperature effects of intraperitoneal apomorphine hydrochloride administered
to male rats . . . . . . . . . .

86

The mean effects of pretreatment (-30 minutes) with thioridazine hydrochloride on
the body temperature effects of intraperitoneal apomorphine hydrochloride administered to male rats
. . .

88

Regression line of the log molar ED50 of
haloperidol lactate, lenperone HCl, chlorpromazine HCl and thioridazine HCl in
stereotyped behavior versus the log molar
ED5o of the same compounds in body temperature (dashed line). The solid line represents the regression line of the log molar
ED5o of haloperidol lactate, lenperone HCl
and chlorpromazine HCl in stereotyped behavior versus the log molar ED50 of the
same compounds in body temperature . .

98

Regression line of the log molar ED5o of
haloper~dol lactate, lenperone HCl, chlorpromazine HCl and thioridazine HCl in
locomotor activity versus the log molar
ED50 of the same compounds in body temperature (dashed line). The solid line represents the regression line of the log molar
ED50 of haloperidol lactate, lenperone HCl
and chlorpromazine HCl in locomotor activity
versus the log molar ED50 of the same compounds in body temperature . . . . . . . . . .
viii

100

LISTOF FIGURES
(continued)
Figure
25.

26.

27.

Page
Regression line of the log molar ED5o of
haloperidol lactate, lenperone HCl, chlorpromazine HCl and thioridazine HCl in
catalepsy versus the log molar ED5o of the
same compounds in body temperature (dashed
line). The solid line represents the
regression line of the log molar ED5o of
haloperidol lactate, lenperone HCl and
chlorpromazine HCl in catalepsy versus
the log molar ED50 of the same compounds
in body temperature.
. . . .

102

Regression line of the log molar ED 50 of
haloperidol lactate, lenperone HCl, chlorpromazine HCl and thioridazine HCl in
locomotor activity versus the log molar
ED5 0 of the same compounds in stereotyped behavior (dashed line). The solid
line represents the regression line of the
log molar ED50 of haloperidol lactate,
lenperone HCl and chlorpromazine HCl in
locomotor activity versus the log molar
ED50 of the same compounds in stereotyped
behavior. . .
. ...

104

Regression line of the log molar ED5o of
haloperidol lactate, lenperone HCl, chlorpromazine HCl and thioridazine HCl in
catalepsy versus the log molar ED5o of the
same compounds in stereotyped behavior
(dashed line).
The solid line represents
the regression line of the log molar ED5o
of haloperidol lactate, lenperone HCl and
chlorpromazine HCl in catalepsy versus the
log molar ED5o of the same compounds in
stereotyped behavior.
. . . .

106

ix

LIST OF FIGURES
(continued)
Figure

28.

Page
Regression line of the log molar ED5o of
haloperidol lactate, lenperone HCl,
chlorpromazine HCl and thioridazine HCl
in catalepsy versus the log molar ED50 of
the same compounds in locomotor activity
(dashed line). The solid line represents
the regression line of the log molar ED50
of haloperidol lactate, lenperone HCl and
chlorpromazine HCl in catalepsy versus the
log molar ED50 of the same compounds in
locomotor activity.
. . . . . . . . . . .

X

108

LIST OF PLATES

Plate
1.
2.
3.
4.

Page
Experimental setup for measuring locomotor activity . . . . . . . . . . . . .

39

Experimental setup for observing stereotyped behavior.
. .....

39

Experimental setup for measuring the degree of catalepsy .
. . . . .

43

Experimental setup for measuring body
temperature . . . . . . . . . . . .

43

xi

INTRODUCTION
There is considerable evidence to suggest that dopamine
(DA), in addition to its role as a precursor of norepinephrine (NE) and ephinephrine, has important physiological
actions in its own right.

One physiological action of DA

seems to be that of a neurotransmitter in the mammalian
brain (Hornykiewicz, 1966).

In addition, there is evidence

that abnormalities of dopaminergic transmission in the central nervous system (CNS) may be of clinical importance.
For example, dopaminergic over activity in the mesolimbic
forebrain may be a primary feature in the etiology of
schizophrenia (Meltzer and Stahl, 1976).
The drugs used to treat schizophrenia act as DA
antagonists in the brain (Snyder et al., 1974; Robinson
et al., 1979).

Drugs such as phenothiazines and butyro-

phenones have been shown in clinical studies to be effective in treating the fundamental symptoms of psychosis
(Snyder et al., 1974).

The results of animal experiments

indicate that their principal mode of action is blockade
of DA receptor sites in the CNS (VanRossum, 1966).

How-

ever, these neuroleptics are generally nonspecific in
their effects upon DA neurons and thus, cause major undesireable side effects.
1
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If new drugs could be discovered that were more structurally selective for different DA systems, then, perhaps
these undesireable side effects could be eliminated.

In

order to develop such drugs, a closer look would have to
be made at different DA systems in an attempt to demonstrate
DA receptors which are topographically distinct and can
thus be selectively regulated by both agonistic and antagonistic agents.

The demonstration of more than one DA

receptor in mammalian CNS is the subject of the research
presented in this thesis.

LITERATURE SURVEY
I.

Dopaminergic Systems in the Central Nervous System
During the past twenty years there has been an in-

creasing realization of the importance of DA as a neurotransmitter in the mammalian brain.

As a result, research

has been focused on demonstrating and mapping out distinctive dopaminergic neuronal tracts in the CNS.

DA is not

present uniformly throughout the brain, but is localized
in a number of discrete pathways that are still being
identified and characterized in the brains of laboratory
animals as well as in postmortem human brains.

There is

good evidence from histofluorescence and biochemical
studies for at least six distinct DA neuronal tracts:
1) retinal DA fibers,

2) preoptic anterior hypothalamic

DA neurons, 3) nigrostriatal DA tract, 4) tubero-infundibular
DA tract, 5) mesolimbic DA tract, and 6) mesocortical DA
neurons (Ungerstedt, 197la).

A schematic presentation of

their location and connections is given in Figure 1.
The largest and by far most thoroughly investigated
DA tract is the nigrostriatal system (Anden

et al., 1964).

The cell bodies for this tract are located in the pars
compacta of the substantia nigra, a pigmented nucleus in
the brainstem'.

These cells give rise to a large pathway
3
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that ascends through the lateral hypothalamus, enters the
crus cerebri in mid-hypothalamus to mix with the myelinated
bundles of the internal capsule, and then fans out in the
globus pallidus, finally terminating in the caudate-putamen
of the neostriatum (Ungerstedt, l97la).

The major function

of the nigrostriatal DA tract is to regulate the neostriatum
in its control of certain motor movements.

Degeneration of

nigral DA neurons is believed to be the cause of Parkinson's
disease (Hornykiewicz, 1975).

Blockade of DA receptors in

the neostriatum with neuroleptic drugs is thought to be the
cause of extrapyramidal syndrome (EPS) (Hornykiewicz, 1975).
The mesolimbic DA neuronal cell bodies are located
dorsal to the interpenduncular nucleus in the ventral tegmental
area and end in terminals just anterior to the caudate
nucleus in the nucleus accumbens septi, the bed

nucleus of

the stria terminalis, and the deep portion of the olfactory
tubercle (Ungerstedt, 1971).

The mesolimbic DA pathway

(Anden et al., 1966; Hokfelt et al., 1974) is involved in
behavioral regulation; according to one popular hypothesis,
schizophrenia is attributed to overactivity of this particular
system (Meltzer and Stahl, 1976).
The presence of cortical DA fibers was first demonstrated by Thierry et al. (1973).

Hokfelt et al. (1974)

was the first to characterize the histochemical distribution
of dopaminergic terminals in rat limbic cortex.

They des-

cribed terminal plexi in gyrus cingul.i, etorhinal cortex,
hippocampus, amygdaloid cortex, the most basal layers of

6

dorsal frontal cortex, and to a minor extent, the prepyriform cortex.

It is tempting to assume that the disturbances

of thinking processes that are an essential feature of many,
if not all, patients in the schizophrenia spectrum are
based on dysfunction of these dopaminergic neurons with
cerebral cortical terminals (Meltzer and Stahl, 1976; Hokfelt
et al., 1974).
Cox and Lee (1979) provide evidence for the presence
of a dopaminergic system within the preoptic anterior
hypothalamus.

It appears that DA receptors present in this

brain region mediate a fall in core temperature in the rat
(Cox and Lee, l977b) and in the cat (Quock and Gale, 1974).
The tubero-infundibular DA tract consists of dopaminergic
neurons that have their cell bodies in the arcuate nucleus
of the hypothalamus and have their terminals in the external
layer of the median eminence.

One function of the tubero-

infundibular dopaminergic neurons is to exert a tonic inhibitory effect on the cells of the anterior pituitary which
synthesize and release prolactin (Hokfelt and Fuxe, 1972).
In addition, there exists a small number of DA-containing
neurons in the eye, which seems to send processes to both the
outer and inner plexiform layers of the retina (Ehringer
and Falck, 1969).

The function of these retinal DA neurons

has not yet been ascertained.

7

II.

Dopaminergic Involvement in the Control of Locomotor
Activity in Rats
Previous experiments suggest that DA may play a role

in the control of locomotor activity in rats.

It was re-

ported by Maj et al. (1971) that rats showed an increase
in locomotor activity following the systemic administration of L-dopa and a dopa decarboxylase inhibitor.

An in-

crease in locomotor activity was also induced by the systemic
administration of amphetamine (Maj et al., 1972a).

In rats

pretreated with pimozide (DA antagonist) or phenoxybenzamine
(alpha-adrenergic blocking agent), L-dopa-stimulation and
that induced by amphetamine was antagonized by pimozide,
while phenoxybenzamine produced complete or partial inhibition of hyperactivity induced by L-dopa or amphetamine (Maj
et al., 1972a).

These results show that in the stimulation

of locomotor activity by these compounds, both central
catecholamines, DA and NE, play a role.
Intracerebral injection of DA or drugs interfering with
DA neurotransmission indicate that locomotion may be related
to mesolimbic DA neurotransmission.

It was found that bi-

lateral injection of DA into the nucleus accumbens of nialamidepretreated rats resulted in an enhancement of locomotor activity (Pijnenburg and VanRossum, 1973).

This is in agreement

with Costal! and Naylor (1975) who reported a dose-dependent
increase in locomotor activity in rats following the bilateral
injection of DA into the nucleus accumbens.

Only a periodic

8

hyperactivity developed after similar injections into the
tuberculum olfactorium and no change in behavior was observed following injections into the nucleus amygdaloideus
centralis (Costall and Naylor, 1975).

Pijnenburg and Van

Rossum (1973) reported only a slight to moderate increase
of locomotor activity following administration of DA into
the caudate nucleus.
When NE was administered into the nucleus accumbens of
rats, an increase in locomotor activity was noted, although
less intense than after DA (Pijnenburg and VanRossum, 1973).
Later studies by Pijnenburg et al. (1975) were performed in
an effort to determine whether the NE-induced increase in
locomotor activity is a result of an action of NE receptors
or by stimulation of DA receptors.

The authors found that

the locomotor stimulation induced by administration of 1
microgram of DA directly into the nucleus accumbens was completely blocked by haloperidol (HAL).

The same dose of HAL

also completely inhibited the effect of 5 micrograms of NE.
HAL is considered as a rather specific DA antagonist both
peripherally and centrally (VanRossum, 1966),with only
relatively small effects on NE receptors (Anden et al., 1970).
Since a rather low dose was used, the effect of HAL upon
the DA and NE-induced locomotor stimulation may be ascribed
to blockade of DA receptors.

Pijnenburg et al. (1975) were

unable to successfully inhibit the NE-induced hypermotility
with phentolamine (alpha-adrenergic antagonist) or propranolol

9
(beta-adrene~gic

antagonist), suggesting that the NE-induced

stimulation of locomotor activity is indirectly associated
with DA mechanisms.
Costall and Naylor (1976) found that systemic administration of DA rece,ptor blockers was able to antagonize the
increase in locomotor activity produced

by bilateral applica-

tion of DA to the nucleus accumbens of nialamide-pretreated
rats.

The neuroleptics used in these studies included the

so-called classical DA repeptor blockers (HAL, fluphenazine,
pimozide, clothiapine), exhibiting a high degree of EPS, and
atypical DA receptor blockers (clozapine, sulpiride, thioridazine (TRZ)), exhibiting a low incidence of EPS.

These

results further support the involvement of dopaminergic
mechanisms in the control of locomotor activity.
There is good evidence to suggest that apomorphine
(APO) stimulates DA receptors in rat brain (Di Chiara and
Gessa, 1978;

Anden et al., 1967; Iversen, 1975).

APO was

found to produce hypermotility in rats following various
subcutaneous doses (Buus Lassen, 1974, 1977).

It was also

found that pretreatment of these rats with the neuroleptics
chlorpromazine (CPZ), TRZ, perphenazine, clozapine, pimozide
and HAL antagonized the hypermotility.

These results are

in agreement with Ljungberg and Ungerstedt (1978), who found
that the systemic administration of

HAL, TRZ, CPZ, clozapine

and sulpiride to rats effectively antagonized the locomotor
activity produced by APO (5.0 mg/kg, s.c.).

10
There is evidence to suggest that the mechanism by which
APO increases locomotor activity is via the direct stimulation of the DA recepto.r in the nucleus accumbens (Kelly
et al., 1975; Iversen et al., 1975).
also be involved.

Other factors may

The ability of phenoxybenzamine to attenu-

ate APO-induced hypermotility in rats suggests that an indirect stimulation of the noradrenergic system plays a role
in APO-induced hypermotility (Maj et al., 1972b).
III.

Dopaminergic Involvement in Apomorphine-Induced
Stereotyped Behavior
Following the administration of APO, a profound change

in the behavioral pattern of the rat occurs.

The charac-

teristic feature of the pattern that emerges is the compulsive repetition of senseless movements.

The discon-

tinuous sniffing initially observed in this behavioral
syndrome is progressively replaced by continuous sniffing,
exploratory activity and repetitive head and limb movements.
When the full-blown apomonphine syndrome is reached, the
rat restricts its locomotor activity to a small area of
the cage while continuously gnawing, biting and licking.
This drug-induced syndrome, characterized by compulsive
behavior o:f a continuous and apparently aimless nature,
is known as "stereotyped.behavior" (DiChiara and Gessa,
1978; Randrup and Munkvad, 1974).
Support for the striatum as the central site of APO
stereotypy was demonstrated very early (Amsler, 1923).

It

11

was found that the ability of APO to produce stereotyped
behavior was abolished following striatal ablation.

In

support of this view, Ernst and Smelik (1966) showed that
when administered in microquantities directly into the
dorsal part of the caudate nucleus or in the globus pallidum,
APO and dopa could induce stereotyped behavior.

When im-

planted in the ventral part of the caudate nucleus, in subthalamic structures or in the substantia nigra, these
agents were unable to induce stereotypy.
Since the substantia nigra appears to send fibers to
the corpus striatum, the finding that this part of the
mesencephalon contains DA is of great interest.

In normal

rats, DA-storing nerve terminals are found in the neostriatum (the caudate nucleus and putamen) (Bertler and
Rosengren, 1959) and DA-containing nerve cells in the substantia nigra, mainly in the pars compacta (Kebabian and
Saavedra, 1976).

After electrolytic lesions in the sub-

stantia nigra or the internal capsule, the histochemical
fluorescence and the DA content of the neostriatum were
markedly reduced.

Removal of the neostriatum produced an

increased fluorescence of the DA nerve cells of the substantia nigra.

This is strong evidence for the existence

of nigro-striatal DA neurons, which probably contain most
or all of the DA present in the neostriatum (Anden et al.,
1964).

It has been suggested that the presence of DA in

this structure is responsible for stereotyped behavior
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and since APO has some structural similarity to DA (Ernst,
1969) it is able to stimulate DA receptors in the neostriatum
and evoke stereotypy.
The mechanism by which APO induces stereotyped behavior
in rats was demonstrated by Ernst (1967) to be the direct
stimulation of DA receptors located in the neostriatum.
Definitive evidence for a direct stimulation by APO of
striatal DA receptors comes from the study of APO effects
in rats pretreated intraventricularly with 6-hydroxydopamine
(6-0HDA) (Schoenfeld and Uretsky, 1972).

I t was reported

that the selective destruction of catecholamine-containing
nerve terminals in the CNS with 6-0HDA caused an increase
in sensitivity of rats to APO, so that the ED
lation was halved.

for stimu50
These results are in agreement with

Ungerstedt (1971) who found that in rats whose substantia
nigra have been bilaterally destroyed with 6-0HDA, a given
dose of APO produced a compulsive gnawing of greater intensity in the lesioned animals than in the intact ones.

These

results demonstrate that APO acts directly by stimulating
DA receptors and that denervation induces a supersensitivity
to its effects.

In addition, rats pretreated with central

DA-antagonists showed no signs of stereotyped behavior following a challenge dose of APO (Niemegeers and Janssen,
1979).

This evidence supports the dopaminergic nature of

this APO-induced effect.
Although it is currently accepted that neostriatal

13
dopaminergic systems are important for the development of
stereotyped behavior patterns, previous studies have shown
that after electrolytic brain lesioning of the nucleus
amygdaloideus centralis (a very old nucleus in the archistriatum), the more intense aspects of APO stereotypy were
abolished (Costall and Naylor, 1973a).

In addition, there

is evidence to suggest that the dopaminergic neurons of
the mesolimbic system may also have a degree of involvement with stereotyped behavior.

It was found that APO-

induced stereotyped behavior was reduced when the ascending
dopaminergic neurons to the mesolimbic system were lesioned.
Lesioning of both the tuberculum olfactorium and nucleus
accumbe.ns abolished the sniffing component of APO-induced
stereotyped behavior while lesion of the stria terminals
was without effect upon APO stereotypy (Costall and Naylor,
1973a).
IV.

Dopaminergic Involvement in Neuroleptic-Induced
Catalepsy
When neuroleptics are given to animals, catalepsy re-

sults.

In this state of sedation, the animals do not move

spontaneously, and do not respond when they are placed
in unusual postures or positions,

~

on a tabletop with

the front limbs elevated using a horizontal bar (Costall
and Naylor, 1974a).

On the other hand, they are not

hypnotized (as they are with barbiturates, etc.), and their
muscular power is retained (in contrast to animals sedated

I
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with muscle relaxants such as meprobamate, chlordiazepoxide,
etc.).

The cataleptic animals react to painful stimuli and

right themselves when placed on their backs (Munkvad et al.,
1968).

When low doses of the narcotic agonist, morphine,

are given to animals, catalepsy occurs, providing the observed
state of immobility is not associated with an increase in
muscle tone greater than observed during neuroleptic
catalepsy.

However, if increasing the dose of the narcotic

agonist causes an immobility associated with marked rigidity,
this state is commonly termed catatonia (Costall and Naylor,
1974a).
Practically all neuroleptics produce in man a neurologic syndrome referred to as EPS.

The majority of extra-

pyramidal reactions consist of "pseudo parkinsonism"
(akinesia, muscular rigidity and tremor) and akathisia (a
syndrome of motor restlessness).

In drug-induced parkin-

sonism, the dominating symptom is usually akinesia.

The

akinetic syndrome produced in laboratory animals by neuroleptic drugs is. referred to as catalepsy.

When testing a

series of compounds suspected of neuroleptic (extrapyramidal)
potency, catalepsy is the most common test used for this
type of evaluation.

The clinical activity of the dopaminergic

antagonists roughly correlates to their ability to induce
catalepsy in experimental animals (Hornykiewicz, 1975).
Although this pharmacological screening procedure holds true
for most typical neuroleptic compounds, a number of atypical
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neuroleptics (TRZ, clozapine and sulpiride) with antipsychotic
potency similar to CPZ, were relatively weak inducers of
catalepsy in rats or devoid of cataleptogenic properties
altogether (Niemegeers and Janssen, 1979; Biirki et al., 1975).
There is neuropharmacologic evidence demonstrating that
dopaminergic antagonists induce catalepsy by acting on the
corpus striatum.

Bilateral electrolytic lesions of the

corpus striatum were observed to attentuate neuroleptic
(CPZ)-induced catalepsy (Keffer et al., 1978).

This is in

agreement with Houma and Fukushima (1978) who found that bilateral lesioning of the striatum weakened the catalepsy
induced by CPZ and TRZ.
The antiemetic compound, metoclopramide, which has been
suggested to decrease striatal dopaminergic activity by
blocking the striatal DA receptors, was found to produce
a dose-dependent catalepsy in mice (Ahtee and Buncombe, 1974)
and in rats (Ahtee, 1975).

In both of these reports, the

induction of catalepsy is associated with a five- to sixfold elevation of striatal homovani1lic acid (HVA), one of
the main metabolites of DA.

This increased striatal HVA

concentration without any decrease in DA content most probably indicates that DA formation is increased.

APO reduced

the catalepsy and the increase in striatal HVA concentration caused by metoclopramide in rats.

These findings in

conjunction with lesion studies previously mentioned suggest that neuroleptics produce catalepsy by blocking DA receptors in the striatum.
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The relative importance of the mesolimbic system in
neuroleptic catalepsy was investigated by placing a lesion
at the rostral level of the hypothalamus to destroy only
the ascending pathway to the mesolimbic areas.

These

studies indicate a critical role for the mesolimbic system
in the mediation of neuroleptic catalepsy since the lesions
caused a marked reduction of the cataleptic actions of
spiroperidol, perphenazine, lenperone (LEN), and TRZ.

It

would, therefore, appear that not only extrapyramidal but
also mesolimbic areas are important for the mediation of
neuroleptic catalepsy (Cost all and Naylor, 1973b).

I t was

further determined that there is a differential involvement
of mesolimbic areas with the behavioral effects of

catalep~y.

The cataleptic action of HAL and LEN was reduced by lesions
of the nucleus accumbens and stria terminalis, however,
ablation of the tuberculum olfactorium did not modify the
cataleptic action of any agent tested (Costall and Naylor,
1974b).

Even though evidence suggests the involvement of

mesolimbic areas, Honma and Fukushima (1978) concluded that
the striatum more than the nucleus accumbens is involved in
producing catalepsy with neuroleptics, since lesions in the
nucleus accumbens had fewer effects on catalepsy than did
those in the striatum.
It would appear that cholinergic as well as dopaminergic
mechanisms are important for the control of catalepsy since
neuroleptic catalepsy can be enhanced or reduced by cholinergic
or anticholinergic agents respectively (Morpurgo, 1962).
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Central cholinergic stimulation by arecholine or pilocarpine
has been found to induce catalepsy.

The cataleptic activity

of these drugs, like that of neuroleptics, was easily
antagonized by anticholinergic agents, especially scopolamine (Zetler, 1971).

It is suggested that the interaction

between the two neurotransmitter systems may take the form
of a reciprocal balance and that since the striatum is rich
not only in DA but also in acetylcholine (ACh) then this
may be a site for the balanced mechanisms (Costall and Naylor,
l974c).
The catalepsy and increased concentration of striatal
HVA

induced by neuroleptic drugs can be antagonized by

anticholinergic drugs (Anden, 1974).

There is also other

evidence that ACh and DA have antagonistic actions in the
striatum.

It has been shown that pilocarpine increases

the concentration of HVA in the striatum and this increase
was antagonized by atropine but not by APO (Ahtee and
Kaariainen, 1974).

When rats were pretreated with alpha-

methylparatyrosine (aMT), neuroleptic catalepsy was
potentiated.

It was, therefore, interesting that cholinergic

catalepsy was also potentiated when catecholamine levels
were reduced by

aMT pretreatment, for this would suggest

thai a catecholaminergic system normally opposes the
cholinergic induced effect and, thus, supports the concept
of a cholinergic-catacholaminergic balance mediating catalepsy (Costall and Naylor, l974c; Ahtee and Kaariainen,
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1974).

Further conceptualization of this ACh-DA balance

by Gianutsos (1979) is based on a consideration of a reciprocal balance in the striatum between ACh and DA
where dopaminergic stimulation inhibits cholinergic
neuronal activity as mentioned previously.

Catalepsy may be

considered as resulting from a net increase in stimulation
of cholinergic receptors in the striatum.

Cholinomimetics

would then produce catalepsy by directly stimulating these
receptors while CPZ would produce catalepsy by blocking DA
receptors and disinhibiting cholinergic neurons leading to
an increase in the efflux of ACh.
As to the mechanism of catalepsy,

support for this

ACh-DA balance in the striatum was offered by Honma and
Fukushima (1978).

They showed that bilateral electro-

coagulation of rat striatum decreased neuroleptic-induced
catalepsy.

If electrocoagulation destroyed not only DA

neurons but also cholinergic neurons, then complete destruction of dopaminergic-cholinergic connections would
cause a reduction in the cataleptogenic activity of HAL.
On the other hand, it was also shown that microinjection
of 6-0HDA into the striatum gradually enhanced the
catalepsy induced by HAL suggesting that removal of the
inhibitory activity of dopaminergic neurons results in an
excitation of cholinergic neurons.
Naylor (1973b)

When Costall and

destroyed the dopaminergic pathways which

supply the extrapyramidal brain regions by lesioning the
lateral hypothalamus, they found that neuroleptic catalepsy
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was enhanced.

If the lesion caused dissruption to the

dopaminergic component of the postulated dopaminergiccholinergic balance operating via the extrapyramidal
nuclei, cholinergic dominance would result.

These studies

offer support for the involvement of an intrastriatal
balance between dopaminergic and cholinergic neurons in
neuroleptic-induced catalepsy.
V.

Dopaminergic Involvement of Apomorphine-Induced
Hypothermia in Rat
Since the introduction of specific DA agonists and

antagonists, evidence has accumulated to suggest that
stimulation of central DA receptors can bring about thermoregulatory changes in several species.

In the cat, the

dose-related fall in body temperature seen after intraventricular injection of DA was blocked by HAL (Kennedy
and Burks, 1974).

In mice, systemically administered APO

produced a dose-related lowering of body temperature.
This hypothermic effect is competitively antagonized by
HAL, pimozide, spiroperiodol, and perphenazine (Fuxe and
Sjoqvist, 1972; Barnett et al., 1972; Buus Lassen, 1974).
APO has been consistently reported to cause a decrease

in the core body temperature of the rat (Kruk, 1972;
Ary et al., 1977; Cox et al., 1978).

These studies also

show that pimozide or HAL can block the hypothermic action
of APO.

It appears that both DA and APO mediate hypo-

thermic responses through activation of DA receptors.
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The site of action of APO has been demonstrated to
reside within the preoptic-anterior hypothalamus of the
rat (Cox and Lee, 1977b, 1979; Cox et al., 1978; Colbec
and Costentin, 1980).

Administration of either DA or APO

into the preoptic-anterior hypothalamus caused an almost
immediate rise in tail skin temperature and a concomitant
fall in core temperature in the rat (Cox et al., 1978).
Following the systemic injection of pimozide, the dosedependent hypothermic response induced by intrahypothalamic
DA or amphetamine was significantly reduced (Cox and Lee,
1979).
It has been reported that tolerance to the hypothermic
action of APO can occur.

Chiel et al. (1974) have shown

that when rats are tested daily with intraperitoneal injections of APO, the hypothermic response of subsequent
injections of APO is reduced.

It was suggested that a

decreased sensitivity of the DA receptor was responsible
for the tolerance to the hypothermic effects of APO.

In

addition, it was found that tolerance to the hypothermic
effects of APO developed in rats following repeated injections.of APO in the rostral hypothalamus at the preopticanterior hypothalamic nuclei (Ary et al., 1977).

This

same study showed that although injections of APO in the
area surrounding the lateral ventricle did induce hypothermia, tolerance to the hypothermic effects of APO was
not observed.

It was therefore proposed that the hypothermic
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effects of APO are mediated via two different types of DA
receptors at two different sites:

1) in the rostral hypo-

thalamus where the receptors develop tolerance; and 2) in
areas surrounding the lateral ventricle, where the receptors
are resistant to tolerance (Ary.et al., 1977).
There is considerable evidence to support the concept
that ACh plays a role in central thermoregulatory mechanisms.
Iontophoretic injection of ACh into the rostral hypothalamic
thermoregulatory centers causes a fall in body temperature
in the rat (Kirkpatrick and Lomax, 1970) and this response
is

abolished by prior systemic injection of atropine in-

dicating a specific effect at cholinergic receptor sites.
Direct injection of atropine into the rostral hypothalamus
of the rat produces hyperthermia, presumably due to blockade of central cholinergic activity (Kirkpatrick and Lomax,
1967).
The interactions between the cholinergic and dopaminergic systems in thermoregulation have been studied by
Glick and Marsanico (1974).

In their studies, it was

found that both APO and pilocarpine induced a dose-dependent
hypothermia in mice.

In addition, when administered to-

gether, the hypothermic effect was greater following a
combination of the drugs than following either drug alone.
In the animals treated with APO, either HAL or scopolamine
were able to antagonize the hypothermic effect, whereas
only scopolamine antagonized pilocarpine-induced hypothermia.

The authors suggest that mechanisms involving
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both dopaminergic and cholinergic neuronal systems contribute to temperature regulation.
to temperature regulation.

These data conflict

These data conflict with Cox

and Lee (1977a) whose studies showed no evidence to support the hypothesis that APO-induced hypothermia involves
a cholinergic link.

They found that the anticholinergic

drugs, scopolamine and atropine were highly effective
antagonists of oxotremorine-induced hypothermia, but in the
same doses they were ineffective against the hypothermic
effect of APO.
VI.

Evidence to Suggest Multiplicity of Dopamine Receptors
in the Central Nervous System
Over the last ten years, experience with DA has led

investigators to consider the DA receptor as something other
than a single entity.

Like other receptor systems, the DA

receptor has been characterized and subdivided into numerous
subtypes.

In the present review, the contention that

multiple DA receptor types exist in the CNS will be supported
by the available evidence.
In studying the pharmacology of tardive dyskinesias,
Klawans (1973) found that tardive dyskinesias can occur
independently of drug-induced parkinsonism and suggested
that there are two separate populations of DA receptors in
the striatum which are differentially susceptible to neuroleptic blockade.

This finding as well as others stimulated

researchers in psychopharmacology to further examine the
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the facilitory and inhibitory nature of DA receptor types.
In 1976, Cools and Van Rossum (1976) hypothesized the
existence of multiple DA receptor types in mammalian nervous tissue.

On the basis of their critical analysis, they

concluded that there exists two electrophysiologically distinct types of DA sensitive units, which are each characterized by their own topographical, pharmacological,
biochemical and ontogenic features.

Histochemical experi-

ments on the rat provide evidence that there exists two
distinct types of DA-terminal structures in the brain.

In

the neostriatum and nucleus accumbens were found structures
marked by diffuse green DA-fluorescence and structures
marked by dotted DA-fluorescence respectively.

It was

suggested that these DA-loaded structures within the brain
contain two populations of DA receptors:

excitatory-

mediating DA receptors (DA ), found in the neostriatum

e

and inhibitory-mediating DA receptors (DA. ), found in the
l

nucleus accumbens.

The DA -structures not only appear later

e

in postnatal development than the DAi-structures, but also
are more sensitive to depletion by aMT and have a higher
turnover rate (Cools and VanRossum, 1976).

It was also

suggested by Cools and VanRossum (1976) that the DA e
receptors are located presynaptically, since both APO and
HAL are able to interact with the same presynaptic DA
receptor (Christiansen and Squires, 1974; Costall and Naylor,
1973c; Seeman, 1974).
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The general feeling that there may exist more than one
type of DA receptor has been explored along a number of
lines.

Thus, in gallamine-immobilized cats, the caudate

nucleus and the nucleus accumbens were perfused by means
of a push-pull cannula and DA was measured in the perfusate.
Following probenicid administration, the net effect of sulpiride, clozapine and TRZ on HVA accumulation was more marked
in the limbic system than in the striatum whereas HAL
and CPZ had a similar effect in the two regions (Bartholini,
1976).

Uzan et al. (1978) found similar results in their

work with mezilamine, a relatively new antipsychotic agent
related to the atypical neuroleptics.

In addition to pro-

ducing a greater accumulation of HVA in the mesolimbic
area than in the striatum of the rat, mezilamine also
showed weak cataleptogenic properties.

This possibly ac-

counts for the fact that atypical neuroleptics display an
antipsychotic action and yet cause less EPS than HAL and
CPZ.
The accumulation of HVA in rodent brain by neuroleptics is thought to be mediated by a neuronal feedback
mechanism triggered by the blockade of postsynaptic DA
receptors (Da Prada and Pletscher, 1966; Roos, 1969).

If

this is so, then the DA receptors located in the striatum
and mesolimbic system should be selectively blocked by the
classical and atypical neuroleptics, respectively.

To test

this hypothesis, Le Fur et al. (1980) studied the in vivo
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displacement of the binding of

3

H-spiroperidol (a high

affinity ligand for the DA receptor) by classical and
atypical neuroleptics.

In this study, no correlation

between regional stimulation of DA turnover and the selective blockade of DA receptors was found.
Although Le Fur et al.

(1980) were unable to demon-

strate a selective blockade of dopaminergic receptors in the
striatum by the classical neuroleptics or in the mesolimbic
system by the atypical neuroleptics, the behavior studies
of Ljungberg and Ungerstedt (1978) were able to support the
hypothesis that there exist different DA receptor types in
the limbic and striatal areas of the brain with differing
sensitivities to antagonist action.

They examined whether

different types of neuroleptic drugs with different clinical
profiles may differ in their ability to antagonize two
different APO-induced behaviors, one characterized by
compulsive gnawing and another characterized by increased
locomotion, and whether a difference in their specificity
would relate to their ability to induce EPS.

It was found

that classical neuroleptic drugs causing high incidence
of EPS (metoclopramide, HAL, CPZ) predominantly antagonized
the APO-induced gnawing, while the atypical neuroleptic
drugs (clozapine, sulpiride, TRZ), showing antipsychotic
potency together with low incidence of EPS, instead
antagonized the APO-induced locomotion (Ljungberg and
Ungerstedt, 1978).
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Biochemical and electrophysiological studies have provided evidence for a new dopaminergic receptor whose function seems to be the regulation of DA influence on postsynaptic cells.

The presynaptic neuron itself might contain

DA autoreceptors because (1) DA and APO can block DA synthesis
in synaptosomal fractions of rat striatum, and this effect
is reversed by neuroleptics (Christiansen and Squires, 1974)
and (2) microiontophoretic application of DA or APO directly
upon the soma of DA neurons located in zona compacta of
substantia nigra decreased the firing of these cells, and
this effect could be blocked by neuroleptic drugs
(Aghajanian, 1977).

These data are consistent with the

observation that low doses of APO are able to depress locomotor function, which is considered to result from a stimulation of presynaptic receptors at doses marginally lower
than those required to stimulate postsynaptic receptors
(DiChiara et al., 1976).
indicate that

3

In addition, binding studies

H-apomorphine has a prediliction for pre-

synaptic DA receptors (Nagy et al., 1978).

The authors

observed that lesioning with 6-0HDA resulted in a selective
and extensive retrograde loss of DA neurons in the substantia nigra, reducing
structure by 76%.

3

H-apomorphine binding in this

This data provides direct evidence for

the presence of DA receptors on DA terminals or axons in
the striatum.

Furthermore, from binding studies of

3

H-

neuroleptics and 3 H-apomorphine in schizophrenic brains,
3
it was hypothesized that 3 H-apomorphine and H-haloperidol
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may be measuring preferentially pre- and postsynaptic DA
receptors, respectively (Lee et al., 1978).

This is con-

sistent with the observation that low doses of APO do not
exacerbate but may alleviate some psychotic symptoms
(Angristet al., 1975).

These data indeed suggest that DA

neurons themselves contain receptors for DA.
Although the application of recept0r labelling assays
has proved useful for many pharmacologists in receptor
identification and localization, the interpretation of data
from in vitro binding studies requires great caution.

Most

authors agree that the critical difficulty in labelling of
receptors with radioactive ligands is that such binding may
reflect binding to non-specific sites and that sometimes,
drugs can displace at non-specific binding sites.

For this

reason, perhaps the most important criteria to fulfill in
order to assess the specificity of binding is drug displacement, necessitating the use of a large number of
antagonists and agonists belonging to different chemical
classes (Laduron, 1980). · With regard to the central DA
receptor,

3

H-haloperidol (Creese et al., 1975), 3 H-

pimozide (Baudry et al., l977),

3

H-domperidone (Baudry

197.9) , and 3 H-sulp1'r1'de (Theodorou et al., 1979)
t !!!:.__·,
1
3
have been used as antagonist ligands, whereas H-dopamine

~

(Creese et al., 1975),

3

H-apomorphine (Seeman et al., 1976)

and 3H-2-amino-6,7-dihydroxytetrahydronaphthalene (ADTN)
(Seeman et al., 1979) are the most important agonist ligands.
It has been suggested that the DA receptor can exist in two
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interconvertible conformations: the antagonist form and
agonist form, since DA antagonists and agonists preferentially
displace the antagonist ligands and agonist ligands respectively (Snyder, 1975).

Significance of this agonist-

antagonist receptor state must remain speculative since
together with the fact that APO has a relatively high affinity
for the HAL binding sites, a newly available 3 H-ligand
3
( H-N-propyl-norapomorphine) which can be selectively directed to either of the two DA receptors has been reported
(Titeler and Seeman, 1979).
In addition to the study of the binding of DA agents to
putative DA receptors, an attempt to increase the knowledge
about the nature of DA receptors has led investigators to
study the DA receptor of neural tissue associated with a
DA-sensitive adenylate cyclase.

In the early seventies,

Greengard's group raised the possibility that the therapeutic effects, as well as the extrapyramidal side effects,
of antipsychotic agents may be attributable, at least in
part, to their ability to block the activation by DA of
specific DA-sensitive adenylate cyclases in the human
brain (Clement-Cormier et al., 1974).

Since then, charac-

terization of this enzyme from the caudate nucleus of rat
brain (Clement-Cormier et al., 1975) as well as geometric
and stereospecific requirements of antagonists of the DA
receptor-cyclase compl.ex ( Clement-Cormier et al. , 1979)
have been reported.

By means of differential and density

29
gradient centrifugation procedures, this DA-sensitive
adenylate cyclase has been regarded as a marker enzyme of
the postsynaptic membrane (Laduron et al., 1976).
It is evident that DA receptors can be divided by biochemical or pharmacological criteria.

These criteria can

also be used to separate those DA receptors which are
linked to the enzyme adenylate cyclase and those which
are not.

The bovine parathyroid provides an example of

a type of DA receptor which stimulates the enzyme adenylate
cyclase, whereas the mammatrophs of the anterior pituatary
contain DA receptors which do not stimulate adenylate cyclase
(Kebabian and Calne, 1979).

It was proposed that the DA

receptors in these two tissues are examples of two distinct
categories of receptor designated by Kebabian and Calne
(1979) as D-1 and D-2 respectively.
As an example of the location of different DA receptors
within a tissue, it is of interest to examine the striatum,
the most extensively studied dopaminergic brain region.
Destruction of the nigra-striatal neurons with 6-0HDA
lesions causes no loss of either stria tal (Krueger-, 1976)
or nigral (Kebabian and Saavedra, 1976) DA-sensitive
adenyl ate cyclase activity.

Conversely, intrastria tal. in-

jection of kainic acid, a rigid glutamic acid analogue,
destroys neuronal cell bodies in the striatum but spares
the dopaminergic nerve terminals; this procedure causes
a substantial loss of striatal DA-sensitive adenylate cyclase

I

''
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activity but does not diminish the content of DA (Di Chiara
et al., 1977;

Hattori andMcGeer, 1977).

In summary,

neither the autoreceptors of the cell bodies in the nigra
nor the autoreceptors of the nigro-striatal terminals appear
to be associated with a DA-sensitive adenylate cyclase.
Although aDA-sensitive adenylate cyclase has been
identified in the substantia nigra as well as the striatum
(Kebabian and Saavedra, 1976), the enzyme occurs on
cellular elements other than the dopaminergic neurons.
Recent studies with kainic acid lesions (to remove postsynaptic DA receptors) and ablations of the cerebral cortex
provide further evidence to distinguish some of the specific
binding sites from the DA-sensitive adenylate cyclase in the
striatum (Schwarcz et al., 1978a).

These experiments imply

that the striatal DA-sensitive adenylate cyclase is located
predominantly on neurons intrinsic to the caudate; in contrast, most of the striatal HAL binding sites are located
on nerve terminals derived from neurons in the cerebral
cortex.
In addition to the D-1 receptors present in the striatal
region, it has been suggested that the DA receptors in
guinea pig and carp retinas are all linked to adenylate
cyclase (Watling et al., 1979).

In order to study these

retinal DA receptors, Watling et al., (1979) utilized
3

H-domperidone which appears to be a novel ligand (Baudry

et al., 1979) specific for D-2 receptor binding sites in

/
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vitro (Laduron and Leysen, 1979).
serve specific binding of

3

Since a failure to ob-

H-domperidone to these tissues

was noted, it implies they contain an apparent homogeneous
population of D-1 receptors.
Recent data indicate that both D-1 and D-2 receptors
exist in the anterior pituitary (Ahnet al., 1979).

Thus,

the adenylate cyclase-linked D-1 anterior pituitary receptor is not associated to prolactin release, but guanosine
triphosphate (GTP) can modulate DA agonist binding to it
(Sibley and Creese, 1979).

On the other hand, the D-2

receptor located on the mammatrophs controls prolactin
release (Caron, 1978), but GTP does not modulate the
affinity of DA agonists for this site (Sibley and Creese,
1979).

Guanine nucleotides also modulate DA agonist bind-

ing to D-1 receptors on striatal cell bodies (Creese et al.,
1979b).

This latter finding is based on the observation

that destruction of striatal cell bodies with kianic acid
causes both the loss of DA activated cyclase (Schwarcz
et al., 1978a) and the loss of the ability of GTP to alter
DA agonist displacement of
sue (Creese et al., 1979a).

3

H-spiroperidol in striatal tisThus, GTP can modulate DA

agonist binding to D-1 receptors in both the striatum
and the anterior pituitary.
Considering the. great variety of criteria that are used
to characterize and subdivide DA receptors into subtypes,
integrating the available data into one unifying concept
has become virtually impossible.

Although a unified
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classificati,on of central DA receptors has not yet been
developed, the available evidence supports the concept of
multiple DA receptor types in mammalian CNS.
Statement of the Problem
Current therapy of schizophrenia involves the use of
neuroleptic agents which are believed to exert their biological activity through the blockade of DA receptors in the
mesolimbic DA tract.

In addition, these drugs block DA

receptors in the corpus striatum and thus cause side effects resulting from impaired DA transmission in the extrapyramidal system.

Neuroleptics also block DA-induced

inhibition of prolactin release as well as other DAregulated nervous functions in the central nervous system.
The therapeutic problems arising from the non-selectivity
of currently available drugs towards DA receptors could be
eliminated, and major advancements into our understanding
of neurological function and pathophysiology could be made
if isoreceptors for DA were demonstrated.

That such iso-

receptors for DA actually exist may be actual fact; however,
identification and pharmacological differentiation of these
DA receptors remains a challenging task.
The present study was undertaken to further support
the hypothesis that there might be multiple receptor types
for DA in mammalian CNS tissue.

A series of neuroleptic
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compounds shall be subjected to a battery of whole animal
screening procedures in an effort to demonstrate gross
differences in potency of activity.

These pharmacological

tests shall include antagonism of APO-induced locomotor
stimulation, stereotyped behavior and thermotropic action
in rats and the induction of catalepsy by the neuroleptic
drug.

Dose response as well as time-activity relationships

shall be determined.

MATERIALS AND METHODS
Animals
Adult male rats of the Wistar strain from Simonsen
Laboratories (Gilroy, California), weighing 150-250g, were
used in all experiments.
in metal cages (50

~
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On arrival, animals were housed
~

20cm) in groups of 15 and exposed

to a fixed light/dark cycle for a period·of not less than
one week prior to experimentation (0800-2000:light; 20000SOO:dark).

Animals were offered a diet of commercially

prepared pellets from Ralston Purina Company (St. Louis,
Missouri) and tap water ad libitum until commencement of
each experiment, at which time all food and water were
withdrawn.

All experiments were conducted in temperature-

controlled facilities maintained at 23+1°C.
Drugs
Apomorphine hydrochloride (APO) obtained from Merck
and Co.

(Rahway, New Jersey) was employed as the dopamine

(DA) agonist at a standard challenge dose of 2.0 mg/kg.
Four neuroleptic compounds were also employed in this study.
From the phenothiazine class, chlorpromazine hydrochloride
(CPZ) was obtained from Smith Kline & French Laboratories
(Philadelphia, Pennsylvania) and thioridazine hydrochloride
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153.18

mol wt 267.31

Structural formulas of Dopamine and the
dopamine agonist, Apomorphine.
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Figure 3., Structural formulas of two butyrophenones,
Haloperidol and Lenperone.
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mol

wt 3 70.56

Structural formulas of two phenothiazines,
Chlorpromazine and Thioridazine.
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(TRZ) from Sandoz Pharmaceuticals (East Hanover, New Jersey).
From the butyrophenone class, haloperidol lactate (HAL)
ampules were obtained from McNeil Laboratories (FortWashington, Pennsylvania) and lenperone hydrochloride (LEN) from
A. H. Robins Company (Richmond, Virginia).

In all experi-

ments, each rat was treated with one of three logarithmicallyspaced doses of either HAL, LEN, CPZ, or TRZ.

Double-

distilled water was used as a control.
All drug solutions were prpeared within 1 hour of
injection using double-distilled water except for APO,
which oxidizes in aqueous solution and was thus prepared
within one minute of injection.

The drugs were all admin-

istered intraperitoneally into the lower left quadrant
of the abdomen using, a 1-ml Tuberculin syringe with a
5/8-inch, 25-gauge needle.

To minimize volume effects,

all drugs were administered in a constant volume of injection of 1.0 ml/kg.
Locomotor Activity
Locomotor activity was measured in a small soundproofed
diffusely illuminated room, using a Model "S" Selective
Activity Meter with printing counter manufactured by Columbus
Instruments (Columbus, Ohio).

Groups of three randomly chosen

rats were placed in a clear plastic cage with bedding material
(45

~

24

~

20cm) and positioned on the activity monitor at

approximately 1200 hours (Plate 1).

At 1530 hours, the

three rats were pretreated with either a neuroleptic or
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Plate 1.

Experimental setup for measuring Locomotor
Activity

Plate 2 .

Experimental setup for observing Stereotyped
Behavior
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double-distilled water.

Thirty minutes later, each rat was

treated with APO at which time monitoring of the group locomotor activity commenced.

Locomotor activity was measured

by the monitor every 6 minutes and the total locomotor
activity score determined for the first 60 minutes following APO injection.
Stereotyped Behavior
Stereotyped behavior was assessed while the animals
were individually housed in clear plastic cages (45

~

24

x 20cm) separated by cardboard screens in a diffusely
illuminated room (Plate 2).

Experiments were conducted

between 1200 and 1600 hours.

The experimental animals

were allowed to acclimate to their environment for at
least l hour prior to commencement of the experiment.

At

1200 hours, the rats were pretreated in a double-blind
fashion with one of the four neuropletic drugs or doubledistilled water; 30 minutes later, all animals were challenged with APO.

Thereafter, stereotyped behavior was

scored at 5-minute intervals for 90 minutes using the
scoring system summarized in Table I.

The individual

score for each animal over the 90-minute period was the
sum of. the 18 5-minute readings.
Catalepsy
For measurement of catalepsy, the test animals were
randomly placed in individual clear plastic cages (45 x 24 x
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Table I.

Scoring System for Estimation of the Intensity
of Stereotyped Behavior .

Assigned Score
1

Behavior Displayed
Behavior indistinguishable from
that displayed by untreated
animals.

2

Periodic sniffing, and/or
repetitive head and limb movements.

3

Continuous sniffing with exploratory activity, andrepetitive head and limb movements.

4

Occasional or periodic gnawing,
biting, or licking, and exploratory activity with continuous
sniffing.

5

Persistent and intense gnawing,
biting, or licking with locomotion restricted to a small area.

6

Compulsive gnawing, biting, or
licking at one location.

Martin and Quock, 1978.
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20 em) in a diffusely illuminated room.
screened from the others

Each cage was

by cardboard screens.

Each rat

was placed in a cage 1 hour prior to drug treatment to
allow adaptation to the new environment.
were made between 1200 and 1600 hours.

All observations
The observation

table was equipped with a 10-cm high horizontal bar adjacent
to the cages and blocked from view with carboard screens
(Plate 3) .

Following treatment with one of the four neuro-

leptic drugs or double-distilled water, each animal was
tested every 15 minutes for catalepsy by placing both front
limbs over the bar.

A cataleptic animal will maintain this

position for various periods of time dependent upon the
degree of catalepsy.

The moment the animal moved off the

bar with both front limbs, the reading from the stop watch
used to measure each animal's duration was then recorded.
Each animal was placed on the bar two times at each 15minute interval within the 90-minute test period to determine an average duration in seconds .

In order to account

for anima:ls maintaining the imposed position for an
infinite period of time, a maximum duration of 120 seconds
was allowed for any observation .

The total bar time (in

seconds) for each animal tested was the sum of six 15minute readings, each of which represent the average of two
test runs .
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Plate 3.

Experimental setup for measuring the degree of .
Catalepsy

Plate 4.

Experimental setup for measuring Body Temperature
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Body Temperature
Core temperature was measured with a Yellow Springs
Tele-Thermometer (Model 43TA) and thermistor probe inserted approximately 4 em. through the rectum while the
animals were individually housed in metal cages (24 x
30 x 15cm) (Plate 4).
1200 and 1600 hours.

Experiments were conducted between
The experimental animals were allowed

to acclimate to the testing environment for at least 1
hour prior to the commencement of the experiment at which
time baseline body temperatures were measured at 15-minute
intervals until consistent readings (~ 0.2°C) were obtained.
The test animals were then pretreated with either a neuroleptic drug or double-distilled water 30 minutes prior to
challenge with either APO or double-distilled water.

The

rectal temperature was then measured every 15 minutes for
the duration of the expected hypothermia,

i.e. 90 minutes.

Statistics
The data obtained for the following time activity relationships:

1) the locomotor activity counts for the 60-

minute scoring period; 2) the cumulative stereotyped behavior scores for each 15-minute interval; 3) the duration
of catalepsy for each 15-minute interval; and 4) the change
in body temperature for each 15-minute interval, were averaged and compared between rats treated with one of three
logarithmically-spaced doses of either HAL, LEN, CPZ or
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TRZ and the double-distilled water control using a Friden
1155 Calculator programed for Dunnett's t-test.
The molar ED

50

of each neuroleptic used in this

study for each of the pharmacological parameters was determined with the use of a Hewlett Packard 25C Calculator.
This calculator was programed for linear regression analysis
in order to obtain values for y-intercept and slope.

In

order to take into account the molecular weight of each
neuroleptic used, throughout all calculations, the dose
of each neuroleptic was expressed as the log mole dose.
The raw data obtained for each dose of neuroleptic tested
in all parameters was expressed as a percentage value.

In

the locomotion studies, the locomotor activity count for
each 60-minute scoring period was expressed as the percentage of maximum inhibition of loco.motor activity.

In

the stereotyped behavior studies, the total stereotyped
behavior score for each animal over a 90-minute period was
expressed as the percentage of maximum inhibition of stereotyped behavior.

In the catalepsy studies, the total bar

time for each animal tested was expressed as the percentage of maximum bar time (720 seconds).

In the body tempera-

ture studies, the maximum drop in body temperature over the
90-minute testing period for each animal was expressed as
the percentage of maximum inhibition of hypothermia.
Within each parameter tested, the log molar ED

50

for

each neuroleptic was determined by entering each of three
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log mole doses of a particular neuroleptic into the calculator as the x-values along with their respective percentage
figures representing the y-values.

By determining the

equation of the line, the log molar ED

for HAL, LEN,
50
CPZ and TRZ within each parameter was calculated by entering 50 as the y-variable and solving for the x-variable.
The 95% confidence limits were also calculated for each
mole ED

50

value.

The log molar ED

50

of each neuroleptic used in this

study for each of the pharmacological parameters were
analyzed quantitatively by means of regression analysis.
Each parameter was paired with each of the others, making
a total of 6 pairings.
molar ED

50

Within each pairing, the log

for HAL, LEN, CPZ and TRZ of one parameter was

entered into the Hewlett Packard 25C as the x-values and
the log molar ED

50

for HAL, LEN, CPZ and TRZ for the second

parameter was entered as the y-values.

A correlation co-

efficient was determined for each pairing as well as the line
of best fit (Table X).

This same method of analysis was

used in determining the correlation coefficient and equation of the line for each of the 6 pairings of parameters
with TRZ excluded from the analysis (Table XI).

RESULTS
1.

Locomotor Activity
APO 2.0 mg/kg produced a significant increase in

locomotor activity when injected intraperitoneally into
rats (Figure 5) compared to a vehicle injection of doubledistilled water.

Vehicle-injected rats also showed no

characteristics of stereotyped behavior whatsoever.

Pre-

treatment with three logarithmically spaced doses of HAL,
LEN, CPZ or TRZ produced a dose-related antagonism of the
increase in locomotor activity induced by APO 2.0 mgjkg
with significant antagonism exhibited by HAL at a dose
of 0.1 mgjkg (Figure 6), LEN at a dose of 0.3 mgjkg
(Figure 7), CPZ at a dose of 2.0 mg/kg (Figure 8), and
TRZ at a dose of 8.0 mgjkg (Figure 9).
2.

Stereotyped Behavior
APO 2.0 mgjkg induced stereotypy when injected intra-

peritoneally into rats.

During the 90-minute scoring

period the rats initially displayed a low intensity of
stereotyped behavior consisting of periodic to continuous
sniffing and repetitive head and limb movements.

Within

30 minutes this progressed to a full blown stereotypy consisting of gnawing, biting or licking at one lo-cation which
frequentlylastedseveral minutes without interruption.
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Table II.

The effect of pretreatment (-30 minutes) with either haloperidol
lactate, lenperone hydrochloride, chlorpromazine hydrochloride
or thioridazine hydrochloride on the locomotor activity effects
of intraperitoneal apomorphine hydrochloride over a 60-minute
period in male rats.

% of Maximum Inhibition
of Locomotor Activity

Drug

Dose

N

Locomotor Activity
Counts

Apomorphine

2.0

6

581. 33 + 208. 61

Haloperidol

0.03
0.06
0.1

6
6
6

418.67 + 132.41
237.83 + 58.47
63.0 + 15.01
-

27.98 + 22.78
59.09 + 10.06
89.16 + 2.58

Lenperone

0.03
0.1
0.3

6
6
6

409.50 + 126.33
206.33 + 71.96
43.17 + 12.45

29.56 + 21.73
64.51 + 12.38
92.57 + 2.14

Chlorpromazine

0.5
1.0
2.0

6
6
6

577.50 + 157.71
219.0 + 82.58
93.0 + 25.55
-

0.66 + 27.13
62.33 + 14.20
83.86 + 4.40

Thioridazine

2.0
4.0
8.0

6
6
6

521.33 + 146. 33
311.0 + 60.95
59.33 + 24.20

10.32 + 25.17
46.50 + 10.48
89.79 + 4.16

Dose is expressed as mgfkg.
Values are reported as the mean + 1.0 SEM.
N represents the number of groups used.
Each group contains 3 rats.

""

00

Figure 5.

The mean effects of intraperitoneal apomorphine hydrochloride or
double-distilled water on the locomotor activity of male rats
pretreated (-30 minutes) with double-distilled water (vertical
bars indicate 1.0 SEM).

Key:

H20fH20 =Double-distilled water 1.0 mljkg followed by
double-distilled water 1.0 mljkg (N=6)

H20fAPO 2.0 =Double-distilled water 1.0 mlfkg followed
by apomorphine HCL 2.0 mgj-kg (N=6)

*

= Using Students t-test, the locomotor activity of
rats treated with APO 2.0 were significantly different from the locomotor activity of rats treated
with double-distilled water (E < 0.05)
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Figure 6.
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The mean effects of pretreatment (-30 minutes) with haloperidol
lactate on the locomotor activity effects of intraperitoneal
apomorphine hydrochloride administered to male rats (vertical
bars indicate 1.0 SEM).

Key:

H20/APO 2.0 = Double-distilled water 1.0 ml/kg followed by
apomorphine HCl 2.0 mgfkg (N=6)
HAL 0.03/APO 2.0 =Haloperidol lactate 0.03 mgfkg followed
by apomorphine HCl 2.0 mg/kg (N=6)
HAL 0.06/APO 2.0 =Haloperidol lactate 0.06 mgfkg followed
by apomorphine HCl 2.0 mgfkg (N=6)
HAL 0.1/APO 2.0 = Haloperidol lactate 0.1 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)

*

= Significantly different from rats injected with H20/APO
2.o <R < o.o5)
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The mean effects of pretreatment (-30 minutes) with lenperone hydrochloride on the locomotor activity effects of intraperitoneal apomorphine
hydrochloride administered to male rats (vertical bars indicate loO SEM)o

Key:

H20/APO 2o0

=Double-distilled water loO mlfkg followed by
apomorphine HCl 2o0 mgfkg (N=6)

LEN 0003/APO 2o0 = Lenperone HCl 0003 mgfkg followed by
apomorphine HCl 2o0 mgjkg (N=6)
LEN Ool/APO 2o0

= Lenperone HCl Ool mg/kg followed by
apomorphine HCl 2o0 mgfkg (N=6)

LEN Oo3/APO 2o0

= Lenperone HCl 0.3 mgfkg followed by
apomorphine HCl 2o0 mgfkg (N=6)

*=

Significantly different from rats injected with H20fAPO
2 00 (~ < 0 005)

,._,.~---~-~-~-~--

54

Q)CSU)

• • •

NNN

000

~~~~
N
.................
0

~~-n
• • •
..... G) G) G)

o~~i5

!-I-l-l

1.~J,+

-

IN

~~

~~~~~~~~~~"

Figure 8.
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The mean effects of pretreatment (-30 minutes) with chlorpromazine
hydrochloride on the locomotor activity effects of intraperitoneal
apomorphine hydrochloride administered to male rats (vertical bars
indicate 1.0 SEM).

Key:

H20/APO 2.0 =Double-distilled water 1.0 mlfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)
CPZ 0.5/APO 2.0 = Chlorpromazine HCl 0.5 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)
CPZ 1.0/APO 2.0 =Chlorpromazine HCl 1.0 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)
CPZ 2.0/APO 2.0 = Chlorpromazine HCl 2.0 mgjkg followed by
apomorphine HCl 2.0 mg/kg (N=6)

*

= Significantly different from rats injected with H20/APO
2.0 (P < 0.05)
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Figure 9.

The mean effects of pretreatment (-30 minutes) with thioridazine
hydrochloride on the locomotor activity effects of intraperitoneal
apomorphine hydrochloride administered to male rats (vertical bars
indicate 1.0 SEM).
Key:

H20/APO 2.0 = Double-distilled water 1.0 ml/kg followed by
apomorphine HCl 2.0 mgfkg (N=6)
TRZ 2.0/APO 2.0 =Thioridazine HCl 2.0 mgjkg followed by
apomorphine HCl 2.0 mg/kg (N=6)
TRZ 4.0/APO 2.0 = Thioridazine HCl 4.0 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)
TRZ 8.0/APO 2.0 = Thioridazine HCl 8.0 mgfkg followed by
apomorphine HCl 2.0 mg/kg (N=6)

*

= Significantly different from rats injected with H20/APO
2.0 (~ < 0.05)
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The behavior displayed then becomes progressively less intense until it becomes undistinguishable from that displayed by untreated animals approximately 60 minutes following treatment with apomorphine.
At all doses tested, HAL, LEN, CPZ and TRZ reduced the
stereotypy score produced by APO at each time interval over
the 90-minute testing period and reduced the total stereotypy score produced by APO in a dose-related manner (Figures
10, 11, 12, 13).

The lowest dose of TRZ used to block APO-

induced stereotypy was still higher than the highest doses
of the other neuroleptics tested.
3.

Catalepsy
The neuroleptic agents, HAL, LEN, CPZ and TRZ were all

found to induce a dose-dependent cataleptic state when injected intraperitoneally into the rat.

However, a cataleptic

state was not induced in rats following intraperitoneal
injection with double-distilled water.

Catalepsy was in-

duced in the rat with HAL at doses of 0.3 to 3.0 mgfkg, LEN
at doses of 0.5 to 2.0 mgfkg, CPZ at doses of 4.0 to 9.0
mgfkg and TRZ at doses of 10.0 to 40.0 mgfkg.

The highest

dose of each neuroleptic tested induced a cataleptic state
which was highly significantly different from vehicle-injected
rats at all time intervals tested (Figures 14, 15, 16, 17).
A cataleptic state was not induced by TRZ at doses less than
10 mgfkg.

This dose of TRZ was still higher than the highest

Table III.

The effect of pretreatment (-30 minutes) with either haloperidol
lactate, lenperone hydrochloride, chlorpromazine hydrochloride or
thioridazine hydrochloride on stereotyped behavior produced by
intraperitoneal apomorphine hydrochloride over a 90-minute period
in male rats.
Total Stereotyped
Behavior Score

% of

Maximum Inhibition
of Stereotyped Behavior

Drug

Dose

N

Apomorphine

2.0

9

55.78 + 0.83

Haloperidol

0.03
0.06
0.1

6
6
6

40.0 + l. 59
31.0 + 2.02
19.83 + 0.48

28.29 + 2.85
44.42 + 3.62
64.44 + 0.86

Lenperone

0.03
0.1
0.3

6
6
6

44.83 + l. 54
29.33 + 2.43
21.17 + l. 30

16.64 + l. 37
47.41 + 4.36
62.05 + 2.33

Chlorpromazine

0.5
1.0
2.0

7
9
8

46. 7l + 2. 02
34.11 + 2. 24
22.63 + 1.36

16.25 + 3.62
38.85 + 4.01
59.44 + 2.44

9.0
12.0
16.0

9
7
7

35.11 + 1.65
26.14 + 0.83
20.57 + 0.75

37.05 + 2.95
53.13 + 1.49
63.12 + 1.35

Thioridazine

Dose is expressed as mgjkg.
Values are reported as the mean + 1.0 SEM.
N represents the number of animals used.
(J)

0
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Figure 10.

~~-~~~~-~~~~~-~--~·-~· --·-~·--~·--~~--~~

The mean effects of pretreatment (-30 minutes) with haloperidol
lactate on stereotyped behavior produced by intraperitoneal
apomorphine hydrochloride administered to male rats (vertical
bars indicate 1. 0 SEM).

Key:

H20/APO 2.0 =Double-distilled water 1.0 mlfkg followed by
apomorphine HCl 2.0 mgfkg (N=9)
HAL .03/APO 2.0 = Haloperidol lactate 0.03 mgfkg followed
by apomorphine HCl 2.0 mgfkg (N=6)
HAL .06/APO 2.0 = Haloperidol lactate 0.06 mgfkg followed
by apomorphine HCl 2.0 mgfkg (N=6)
HAL 0.1/APO 2.0 = Haloperidol lactate 0.1 mgfkg followed
by apomorphine HCl 2.0 mgfkg (N=6)

*
**

= Significantly different from rats injected with H20/APO
2.0

CR

< o.o5)

= Highly significantly different from rats. injected with
H20fAPO 2.0 (P < 0.01)
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Figure 11.

-~~-·--·-- -~~

The mean effects of pretreatment (-30 minutes) with lenperone
hydrochloride on stereotyped behavior produced by intraperitoneal
apomorphine hydrochloride administered to male rats (vertical bars
indicate 1.0 SEM).
Key:

H20/APO 2.0

= Double-distilled

water 1.0 mlfkg followed by
apomorphine HCl 2.0 mgfkg (N=9)

LEN .03/APO 2.0 = Lenperone HCl 0.03 mg/kg followed by
apomorphine HCl 2.0 mgfkg (N=6)
LEN .01/APO 2.0 = Lenperone HCl 0.1 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)
LEN 0.3/APO 2.0 = Lenperone HCl 0.3 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)

*
**

= Significantly different from rats injected with
H20/APO 2.0 (P < 0.05)
= Highly significantly different from rats injected
with H20fAPO 2.0 (P < 0.01)
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The mean effects of pretreatment (-30 n1inutes) with chlorpromazine
hydrochloride on stereotyped behavior produced by intraperitoneal
apomorphine hydrochloride administered to male rats (vertical bars
indicate 1.0 SEM).

Key:

H20/APO 2.0 =Double-distilled water 1.0 mljkg followed by
apomorphine HCl 2.0 mg/kg (N=9)
CPZ 0.5fAPO 2.0 = Chlorpromazine HCl 0.5 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=7)
CPZ l.OfAPO 2.0 = Chlorpromazine HCl 1.0 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=9)
CPZ 2.0/APO 2.0 = Chlorpromazine HCl 2.0 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=8)

** =

Highly significantly different from rats injected with
H20/APO 2.0 (P < 0.01)

66
cg cg cg

•

•

•

cg~~~

N~~~
o,,,

~Lncg~
. .
......

•

cg

-

C\1

ONNN

~fj~~

OX4 c

-

i

- · - -

*~·
* ,,. •

..

~p

p,

~''
••
,.
,,

,;

.,.

I

~~

....

'

~

I

-

LD

I

-.

l'

I

-

cg
~

:r--.(

..... .....
.,..._
cg

~

I

I

,/
-~

~

*
*

* I

.,.. •

:

I

I

~
v

*~

/'

II

, I
,,- I

,
•
.
,

,,.,.

=~

I

g,

••
•••

•••
•
••

m ....z.

*
*

......

...

......

...

cg

I

I

I

I
LD

I

I

cg

'2:
H
1-

~-~ --~~------------~

Figure 13.

'~~

-~~~~~~--

~~~~-

The mean effects of pretreatment (-30 minutes) with thioridazine
hydrochloride on stereotyped behavior produced by intraperitoneal
apomorphine hydrochloride administered to male rats (vertical bars
indicate 1.0 SEM).

Key:

H20/APO 2.0 = Double-distilled water 1.0 mljkg followed by
apomorphine HCl 2.0 mgjkg (N=9)
TRZ 9/APO 2.0 = Thioridazine HCl 9.0 mgjkg followed by
apomorphine HCl 2.0 mgjkg (N=9)
TRZ 12/APO 2.0 = Thioridazine HCl 12.0 mgjkg followed by
apomorphine HCl 2.0 mgjkg (N=7)
TRZ 16/APO 2.0 = Thioridazine HCl 16.0 mgjkg followed by
apomorphine HCl 2.0 mgfkg (N=7)

*
**

= Significantly different from rats injected with H20/APO
2 . 0 (_)C < 0 . 05)

= Highly significantly different from rats injected with
H20/APO 2.0
< 0.01)

CR
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Table IV.

The effect of treatment with either haloperidol lactate, lenperone
hydrochloride, chlorpromazine hydrochloride or thioridazine hydrochloride on the ability of male rats to maintain a cataleptic position over a 90-minute testing period.

% of Maximum
Drug

Dose

N

Total Bar Time

Bar Time

Haloperidol

0.3
l.O
3.0

7
7
7

120.57 + 21.25
377.71 + 38.17
654.14 + 15.66

16.75 + 2.95
52.46 .± 5.30
90.85 + 2.18

Lenperone

0.5
l.O
2.0

8
9
8

91. 38 + 14. 32
305.33 + 56.51
588.88 + 25.33

12.69 + 1.99
42.41 + 7.85
81.79 + 3.52

Chlorpromazine

4.0
6.0
9.0

8
6
6

72.25 + 10.09
346.33 + 22.77
598.00 + 32.42

10.03 + 1.40
48.10 + 3.16
83.06 + 4.50

10.0
20.0
40.0

7
8
8

69.57 + 8.04
314.25 + 21.41
541.12+12.28

9.66 + 1.12
43.64 + 2.97
75.16 + 1.70

Thioridazine

Dose is expressed as mgjkg. Values are reported as the mean + 1.0 SEM.
N represents the number of animals used. Total bar time is expressed in
seconds.

m
CD

--~·---~~·

Figure 14.

~~

~~~

The mean effects of treatment with haloperidol lactate on the
ability of male rats to maintain a cataleptic position (vertical
bars indicate 1.0 SEM)

Key:

H20

=

Double-distilled water 1.0 mlfkg (N=6)

HAL 0.3 = Haloperidol lactate 0.3 mg/kg (N=7)
HAL 1.0 = Haloperidol lactate 1.0 mg/kg (N=7)
HAL 3.0 = Haloperidol lactate 3.0 mgfkg (N=7)

*
**

~

Significantly different from rats injected with
H20 (P < 0.05)

= Highly significantly different from rats injected
with H20 (P < 0.01)
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Figure 15.

-~-~-~~-~·--~~--~~··--~--.

The mean effects of treatment with 1enperone hydrochloride on
the ability of male rats to maintain a cataleptic position
(vertical bars indicate 1.0 SEM).

Key:

H20 =Double-distilled water 1.0 mlfkg (N=6)
LEN 0.5 = Lenperone HCl 0.5 mgfkg (N=8)
LEN 1.0 = Lenperone HCl 1.0 mgfkg (N=9)
LEN 2.0 = Lenperone HCl 2.0 mgfkg (N=8)

*
**

= Significantly different from rats injected with
H20 (P < 0.05)
= Highly significantly different from rats injected with
H20 (P < 0.01)
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Figure 16.

--~~~· -·-·~-~-~-.

The mean effects of treatment with chlorpromazine hydrochloride on
the ability of male rats to maintain a cataleptic position (vertical
bars indicate 1.0 SEM).

Key:

H20 = Double-distilled water 1.0 ml/kg (N=6)
CPZ 4.0 = Chlorpromazine HCl 4.0 mgfkg (N=8)
CPZ 6.0 = Chlorpromazine HCl 6.0 mgfkg (N=6)
CPZ 9.0 = Chlorpromazine HCl 9.0 mgfkg (N=6)

*
**

= Significantly different from rats injected with
H20 <R < 0.05)
= Highly significantly different from rats injected
with H20 (P < 0.01)
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Figure 17.

~--·-·-~

.. ~~~~

The mean effects of treatment with thioridazine hydrochloride on
the ability of male rats to maintain a cataleptic position (vertical
bars indicate 1.0 SEM).

Key:

H20 = Double-distilled water 1.0 ml/kg (N=6)
TRZ 10 = Thioridazine HCl 10.0 mgjkg (N=7)
TRZ 20 = Thioridazine HCl 20.0 mgjkg (N=S)
TRZ 40 = Thioridazine HCl 40.0 mgjkg (N=S)

*
**

= Significantly different from rats injected with
H20 <R < 0.05)
= Highly significantly different from rats injected
with H20 (P < 0.01)
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doses of the other neuroleptics tested.
4.

Body Temperature
APO 2.0 mgfkg produced a dose-related hypothermia when

injected intraperitoneally into rats.

The maximum drop in

body temperature, -1.08° + 0.12°C (mean~ SEM), occurred
15 minutes following the injection of APO.

Pretreatment

with HAL at 0.1 and 0.3 mgfkg highly significantly antagonized the maximum drop in body temperature induced by APO
2.0 mgfkg (Figure 19).

Pretreatment with HAL 0.03 mg/kg

potentiated the hypothermic action of APO between 30 and
90 minutes following the APO injection (Figure 19).

When

tested alone, intraperitoneal HAL 0.3 mg/kg did not significantly affect body temperature in the rat (Figure 18).
Pretreatment with LEN at 0.3 and 1.0 mgfkg highly significantly antagonized the maximum drop in body temperature
induced by APO 2.0 mgfkg (Figure 20).

Pretreatment with

LEN 0.1 mg/kg potentiated the hypothermic action of APO
between 30 and 90 minutes following the APO injection to a
degree that was not significant (Figure 20).

When tested

alone, intraperitoneal LEN 1. 0 mgfkg did not significantly
affect body temperature in the rat (Figure 18).

Pretreat-

ment with CPZ at 1.7 and 3.0 mgfkg highly significantly
antagonized the maximum drop in body temperature induced by
APO 2.0 mg/kg (Figure 21).

Pretreatment with CPZ 1.0 mgfkg

potentiated the hypothermic action of APO between 30 and 90
minutes following the APO injection to a significant degree

~~""
Table V.

I

The effect of pretreatment (-30 minutes) with either haloperidol lactate,
lenperone hydrochloride, chlorpromazine hydrochloride or thioridazine
hydrochloride on the rectal temperature effects of intraperitoneal
apomorphine hydrochloride over a 90-minute testing period in male rats.

% of

Drug

Dose

N

Maximum Drop in
Body Temperature

Apomorphine

2.0

9

-1.08 + 0.12

Haloperidol

0.03
0.1
0.3

6
6
6

-l. 03 + 0.08
-0.50 + 0.15
0
-

4.32 + 7.81
53.7 + 13.94
100
+ 0

Lenperone

0.1
0.3
1.0

6
6
6

-0.97 + 0.15
-0.30 + 0.11

10.49 + 14.28
72.22 + 10.14
100
+ 12.87

1.0
1.7
3.0

8
6
9

-1.14 + 0.09
-0.73 + 0.13
-0.39 + 0.09

-5.32 + 8.38
32.10 + 12.11
63.99 + 7.94

1.0
1.7
3.0

6
6
6

-1.12 + 0.13
-0.72 + 0.09
-0.30 + 0.10

-3.40 + 12.05
33.64 + 8.76
72.22 + 9.56

Chlorpromazine

Thioridazine

0

Maximum Inhibition of Hypothermia

Dose is expressed as mgfkg.
Values are reported as the mean + 1.0 SEM.
N represents the number of animals used.
-'I
(0

--~----~~~~-~~~.~~

Figure 18.

-~~·~~~

The mean effects of intraperitoneal haloperidol lactate,
lenperone hydrochloride, chlorpromazine hydrochloride or
thioridazine hydrochloride on the rectal temperature of
male rats (vertical bars indicate 1.0 SEM).

Key:

H20 = Double-distilled water 1.0 mlfkg (N=6)
HAL 0.3 =Haloperidol lactate 0.3 mgfkg (N=6)
LEN 1.0 = Lenperone HCl 1.0 mgfkg (N=6)
CPZ 3.0 = Chlorpromazine HCl 3.0 mgfkg (N=6)
TRZ 3.0 = Thioridazine HCl 3.0 mgfkg (N=6)

*

= Significantly different from rats injected with H20
(P < 0.05)
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Figure 19.

The mean effects of pretreatment (-30 minutes) with haloperidol
lactate on the body temperature effects of intraperitoneal apomorphine
hydrochloride administered to male rats (vertical bars indicate 1.0
SEM).

Key:

H20/APO 2.0 = Double-distilled water 1.0 mlfkg followed by
apomorphine HCl 2.0 mgfkg (N=9)
HAL .03/APO 2.0 =Haloperidol lactate 0.03 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)
HAL 0.1/APO 2.0 =Haloperidol lactate 0.1 mgfkg followed
by apomorphine HCl 2.0 mgfkg (N=6)
HAL 0.3/APO 2.0 =Haloperidol lactate 0.3 mgfkg followed
by apomorphine HCl 2.0 mgfkg (N=6)

*
**

= Significantly different from rats injected with H20/APO
2. 0 (~ < 0. 05)
= Highly significantly different from rats injected with
H20/APO 2.0 (~ < 0.01)
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The mean effects of pretreatment (-30 minutes) with lenperone
hydrochloride on the body temperature effects of intraperitoneal
apomorphine hydrochloride administered to male rats (vertical
bars indicate 1.0 SEM).

Key:

H20fAPO 2.0 = Double distilled water 1.0 mlfkg followed by
apomorphine HCl 2.0 mgfkg (N=9)
LEN 0.1/APO 2.0 = Lenperone HCl 0,1 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)
LEN 0.3/APO 2.0 = Lenperone HCl 0.3 mgjkg followed by
apomorphine HCl 2.0 mgfkg (N=6)
LEN 1.0/APO 2.0 = Lenperone HCl 1.0 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)

*
**

= Significantly different from rats injected with
H20/APO 2.0 CE < 0.05)
= Highly significantly different from rats injected with
H20/APO 2.0 CE < 0.01)
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Figure 21.
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The mean effects of pretreatment (-30 minutes) with chlorpromazine
hydrochloride on the body temperature effects of int.raperitoneal
apomorphine hydrochloride administered to male rats (vertical bars
indicate 1.0 SEM)
Key:

H20/APO 2.0 =Double-distilled water 1.0 mlfkg followed by
apomorphine HCl 2.0 mgfkg (N=9)
CPZ 1.0/APO 2.0 = Chlorpromazine HCl 1.0 mgjkg followed by
apomorphine HCl 2.0 mgfkg (N=8)
CPZ 1.7/APO 2.0 = Chlorpromazine HCl 1.7 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)
CPZ 3.0/APO 2.0 = Chlorpromazine HCl 3.0 mgjkg followed by
apomorphine HCl 2.0 mgjkg (N=9)

*
**

= Significantly different from rats injected with H20/APO
2.0 (~ < 0.05)

= Highly significantly different from rats injected with
H20JAPO 2.0

(~

<

0.01)

87

,

.

__

.

~

<"')

ONNN

~~~~

ox~o

\

\

\

\

'\

\

\

~
I

\

\

\

r1
/
I

.

.

~

Ill

~

~

U~<ZW~

1

~z

~OQ~

I

.

-.

~

Ill

1

1

-

u

~w~~

0

II

~~~~ - - ' - '

Figure 22.
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The mean effects of pretreatment (-30 minutes) with thioridazine
hydrochloride on the body temperature effects of intraperitoneal
apomorphine hydrochloride administered to male rats (vertical bars
indicate 1.0 SEM).
Key:

H20/APO 2.0 = Double-distilled water 1.0 ml/kg followed by
apomorphine HCl 2.0 mgfkg (N=9}
TRZ 1.0/APO 2.0 = Thioridazine HCl 1.0 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)
TRZ 1.7/APO 2.0 = Thioridazine HCl 1.7 mgfkg followed by
apomorphine HCl 2.0 mgfkg (N=6)
TRZ 3.0/APO 2.0 = Thioridazine HCl 3.0 mgfkg followed by
apomorphine Hcl 2.0 mgfkg (N=6}

*

= Significantly different rats injected with H20/APO 2.0

**

= Highly significantly different from rats injected with

(): < 0.05)

H20fAPO 2.0

(): < 0.01)
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at the 45 and 60-minute time intervals (Figure 21).

When

tested alone, CPZ 3.0 mgfkg significantly lowered the body
temperature of the rat 30 and 45 minutes following intraperitoneal injection (Figure 18).

The body temperature

dropped to a maximum of -0.48 _! 0.18°C (mean_! SEM) at the
45-minute time interval.

The maximum drop in body tempera-

ture induced by APO 2.0 mgfkg was highly significantly
antagonized when rats were pretreated with TRZ 3.0 mgfkg
and significantly antagonized with a pretreatment dose of
1.7 mgfkg (Figure 22).

Pretreatment with TRZ 1.0 mgfkg

potentiated the hypothermic action of APO between 30 and 90
minutes following the APO injection to a degree that was
not significant (Figure 21).

When tested alone, TRZ 3.0

mgfkg did not significantly affect body temperature in the
rat (Figure 17).
5.

Regression Analysis
The log molar ED

50

of HAL, LEN, CPZ, and TRZ of one of

the four pharmacological parameters measured were .compared
to each of the other three using regression analysis.

In

this analysis, the correlation coefficients of body temperature compared to stereotyped behavior, locomotor activity and catalepsy were 0.92, 0.94 and 0.92, respectively,
while in the analysis of the other three pairings of
pharmacological parameters, all had correlation coefficients
of 0.99 (Table X).
ED

50

In this analysis, only the log molar

of TRZ on its ability to block APO-induced hypothermia

91

compared to the log molar ED

50

of TRZ on its ability to

block APO-induced stereotyped behavior and locomotor
activity and its ability to induce catalepsy deviates
from the regression line when comparing one pharmacological
parameter to each of the others (Figures 23, 24, 25, 26,
27, 28).
In order to further examine this observation, TRZ
was excluded from the regression analysis and only the log
molar ED

50

values of HAL, LEN and CPZ between one pharma-

cological parameter and each of the others were compared.
The correlation coefficients of body temperature compared
to stereotyped behavior, locomotor activity and catalepsy
improved to 0.99, 0.98 and 0.99, respectively,

(Table XI).

The regression lines generated in this analysis further
demonstrate the deviation of TRZ from the regression line
when body temperature is compared to each of the other
pharmacological parameters (Figures 23, 24, 25, 26, 27, 28).

-~~~~~~~---'~--~~~~~~~~~__:___~.

Table VI.

The ED5o and mole ED5o of haloperidol lactate on its ability to block
apomorphine hydrochloride-induced effects and to induce catalepsy.

Parameters

mole ED

ED 50

Body Temperature

0.09 (0.07-0.11)

1.94

X

Stereotyped Behavior

0.06 (0.05-0.07)

1.40

X

10 -7 (1.54
-7
10
(1.26

Locomotor Activity

0.05 (0.04-0.06)

1.02

X

10

Catalepsy

0.87 (0.57-1.32)

1.87

X

10

-7
-6

50

X

10 -7 - 2.45
-7
10
- 1.56

(8.28

X

10

(1.23

X

10

X

-8
-6

X

10 -7)
-7
10 )

- 1.25

X

10

- 2.83

X

10

X

-7
-6

)
)

Values for ED 50 and mole ED
are reported as mgfkg (95% C.L.) and molesjkg (95%
50
C.L.), respect1vely.

<!)

tv

Table VII.

The ED5 0 and mole ED50 of lenperone hydrochloride on its ability to
block apomorphine hydrochloride-induced effects and to induce catalepsy.

Parameters

mole ED

ED 50

Body Temperature

0.23 (0.17-0.32)

5.74 X 10

Stereotyped Behavior

0.14 (0.12-0.17)

3.54 X 10

Locomotor Activity

0.66 (0.04-0.09)

1.52 X 10

Catalepsy

1.09 (0.98-1.22)

2.68 X 10

-7
-7
-7
-6

(4.20 X 10
(2.94 X 10
(1.02 X 10
(2.40 X 10

50
-7
-7
-7
-6

- 7.86 X 10
- 4.25 X 10
- 2.24 X 10
- 3.00 X 10

-7
-7
-7
-6

)
)
)
)

Values for ED 50 and mole ED
are reported as mgfkg (95% C.L.) and molesjkg (95%
50
C.L.) respectively.

(D

w
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Table VIII.

The EDso and mole ED 50 of chlorpromazine hydrochloride on its ability
to bloCR apomorphine nydrochloride-induced effects and to induce
catalepsy.

Parameters

mole En

ED 50

50

Body Temperature

2.37 (2.07-2.70)

6.66

X

10 -6 (5.83

X

10 -6 - 7.61

X

10 -6 )

Stereotyped Behavior

1.46 (1.43-1.49)

4.11

X

10 -6 (4.02

X

10 -6 - 4.20

X

10 -6 )

Locomotor Activity

1.02 (0.81-1.28)

2.86

X

10 -6 (2.27

X

10 -6 - 3.61

X

10-6 )

Catalepsy

6.20 (5.97-6.44)

1.74

X

10

X

10

X

10

-5

(1.68

-5

- 1.81

-5

)

Values for ED50 and mole ED5 0 are reported as mgfkg (95% C.L.) and moles/kg (95%
C.L.), respectively.
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Table IX.

The ED50 and mole ED5o of thioridazine hydrochloride on its ability to
block apomorphine hydrochloride-induced effects and to induce catalepsy.

Parameters

mole ED

ED 50
5.32

X

10 -6 (4.62

Stereotyped Behavior 11.73 (8.80-15.64)

2.88

X

10

Locomotor Activity

1.00

X

10

Body Temperature

Catalepsy

2.!7 (1.88-2.50)

4.08 (3.27-5.09)
23.28 (22.08-24.53)

Values for ED5o and mole ED50
(95% C.L. ), respectively.

5.72 X 10

-5
-5
-5

50
X

10 -6 - 6,13

(2.16

X

10

(8,20

X

10

(5.42 X 10

-5
-6
-5

X

10-6 )

- 3.84

X

10

- 1.28

X

10

- 6.03 X 10

-5
-5
-5

)
)
)

are reported as mgjkg (95% C.L.) and molesjkg

<D
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Table X.

Regression analysis of the logarithm of the molar ED5o of haloperidol
lactate, lenperone hydrochloride, chlorpromazine hydrochloride and
thioridazine hydrochloride in a series of four pharmacological parameters;
body temperature, stereotyped behavior, locomotor activity and catalepsy.

Analysis of:

y-intercept

slope

r

------

Body Temperature versus
Stereotyped behavior

l. 74

1.29

0.92

Body Temperature versus
Locomotor Activity

1.08

1.22

0.94

Body Temperature versus
Catalepsy

-0.03

0.86

0.92

Stereotyped Behavior versus
Locomotor Activity

-0.75

0.92

0.99

Stereotyped Behavior versus
Catalepsy

-1.21

0.66

0.99

Locomotor Activity versus
Catalepsy

-0. 7l

0.72

0.99

(Q

m

~-~~~~~~~·-~~~

Table XI.

Regression analysis of the logarithm of the molar ED 50 of haloperidol
lactate, lenperone hydrochloride and chlorpromazine hydrochloride (excluding thioridazine hydrochloride in this analysis) in a series of
four pharmacological parameters; body termperature, stereotyped behavior, locomotor activity and catalepsy.

Analysis of:

y-intercept

slope

r

Body Temperature versus
Stereotyped Behavior

-0.41

0.96

0.99

Body Temperature versus
Locomotor Activity

-0.48

0.99

0.98

Body Temperature versus
Catalepsy

-1.40

0.65

0.99

Stereotyped Behavior versus
Locomotor Activity

-0.03

1.03

0.99

Stereotyped Behavior versus
Catalepsy

-1.10

0.68

0.99

Locomotor Activity versus
Catalepsy

-1.11

0.66

0.99

(D
....:)

~~-·,,~~~

Figure 23.

~
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Regression line of the log molar ED5 0 of haloperidol lactate,
lenperone HCl, chlorpromazine HCl and thioridazine HCl in
stereotyped behavior versus the log molar ED50 of the same
compounds in body temperature (dashed line).
The solid line
represents the regression line of the log molar ED5o of
haloperidol lactate, lenperone HCl and chlorpromazine HCl in
stereotyped behavior versus the log molar ED5o of the same
compounds in body temperature.
(vertical and horizontal bars
indicate 95% confidence limits; for values, see Tables VI
through IX; for y-intercept, slope and r values see Tables
X and XI).
Key:

HAL

=

Haloperidol lactate

LEN

=

Lenperone hydrochloride

CPZ

= Chlorpromazine hydrochloride

TRZ = Thioridazine hydrochloride
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Figure 24.
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Regression line of the log molar ED5o of haloperidol lactate,
lenperone HCl, chlorpromazine HCl and thioridazine HCl in
locomotor activity versus the log molar ED5o of the same
compounds in body temperature (dashed line). The solid line
represents the regression line of the log molar EDso of
haloperidol lactate, lenperone HCl and chlorpromazine HCl in
locomotor activity versus the log molar ED5o of the same compounds in body temperature.
(vertical and horizontal bars
indicate 95% confidence limits; for values, see Tables VI
through IX; for y-intercept, slope and r values, see Tables
X and XI).
Key:

HAL = Haloperidol lactate
LEN

=

Lenperone hydrochloride

CPZ = Chlorpromazine hydrochloride
TRZ

=

Thioridazine hydrochloride
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Figure 25.

·-~~-~

!

~~~~-·~--~----~~~---·'--·---~---·

Regression line of the log molar ED 50 of haloperidol lactate,
lenperone HCl, chlorpromazine HCl and thioridazine HCl in
catalepsy versus the log molar. ED5o of the same compounds in
body temperature (dashed line).
The solid line represents the
regression line of the log molar ED5o of haloperidol lactate,
lenperone HCl and chlorpromazine HCl in catalepsy versus the
log molar ED5o of the same compounds in body temperature.
(vertical and horizontal bars indicate 95% confidence limits;
for values, see Table VI through IX; for y-intercept, slope
and r values, see Tables X and XI).
Key:

HAL = Haloperidol lactate
LEN = Lenperone hydrochloride
CPZ = Chlorpromizaine hydrochloride
TRZ

=

Thioridazine hydrochloride
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Figure 26.
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Regression line of the log molar ED 50 of haloperidol lactate,
lenperone HCl, chlorpromazine HCl and thioridazine HCl in
locomotor activity versus the log molar ED50 of the same compounds in stereotyped behavior (dashed line). The solid line
represents the regression line of the log. molar ED50 of
haloperidol lactate, lenperone HCl and chlorpromazine HCl in
locomotor activity versus the log molar ED5o of the same compounds in stereotyped behavior.
(vertical and horizontal bars
indicate 95% confidence limits; for values, see Tables VI
through IX; for y-intercept, slope and r values, see Tables
X and XI).

Key:

HAL

=

Haloperidol lactate

LEN = Lenperone hydrochloride
CPZ

=

Chlorpromazine hydrochloride

TRZ

=

Thioridazine hydrochloride
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Figure 27.

L
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Regression line of the log molar ED 50 of haloperidol lactate,
lenperone HCl, chlorpromazine HCl and thioridazine HCl in
catalepsy versus the log molar ED5o of the same compounds in
stereotyped behavior (dashed line). The solid line represents
the regression line of the log molar ED50 of haloperidol lactate,
lenperone HCl and chlorpromazine HCl in catalepsy versus the
log molar ED5o of the same compounds in stereotyped behavior.
(vertical and horizontal bars indicate 95% confidence limits;
for values, see Table VI through IX; for y-intercept, slope
and r values, see TablesX and XI).
Key:

HAL = Haloperidol lactate
LEN = Lenperone hydrochlorid
CPZ = Chlorpromazine hydrochloride
TRZ = Thioridazine hydrochloride
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Figure 28.
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Regression line of the log molar ED5o of haloperidol lactate,
lenperone HCl, chlorpromazine HCl and thioridazine HCl in
catalepsy versus the log molar ED5o of the same compounds in
locomotor activity (dashed line). The solid line represents
the regression line of the log molar ED5 0 of haloperidol
lactate, lenperone HCl and chlorpromazine HCl in catalepsy
versus the log molar ED5o of the same compounds in locomotor
activity.
(vertical and horizontal bars indicate 95% confidence limits; for values, see Table VI through IX; for yintercept, slope and r values, see Tables X and XI).
Key:

HAL

=

Haloperidol lactate

LEN = Lenperone hydrochloride
CPZ

=

Chlorpromazine hydrochloride

TRZ = Thioridazine hydrochloride

109

0
~

vI

I

I()
I

<D
I

.<sdat o~o;,
("6>11 sa1ow) os ·a·3 3lO~ £~Ol

1'1

DISCUSSION
The ultimate objective of this research project was
to provide further evidence supporting a hypothesis of
multiple receptor types for DA in mammalian CNS tissue.
The research in this thesis was to investigate the possibilities of gross differences in selectivity for DA
receptors by a series of neuroleptic compounds.

In the

past, few investigators had considered the DA receptor
as anything other than a single entity, but investigators
have since turned to determining whether there are DA receptor subtypes.

A stage has now been reached where there

exist numerous subtypes.

However, since these have been

created from the use of diverse techniques and often times
from a compilation of data from different laboratories, the
evidence for the existence of multiple receptor types for
DA is not always entirely convincing.

In this study, all

the data was gathered and compiled from standardized procedures in one laboratory and treated by a method of analysis
similar to that successfully employed by Portoghese (1965)
in investigating analgesic receptors.
In this research project, HAL, LEN, CPZ and TRZ were
subjected to a battery of whole animal screening procedures.
110
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These pharmacological tests included antagonism of APOinduced locomotor activity, stereotyped behavior and
hypothermia and induction of catalepsy in rats.
ED

50

Systemic

values as well as time-activity relationships were

determined.
The present study indicates that the observed effects
of APO are due to an agonistic effect on dopaminergic
mechanisms.

There is convincing evidence in the litera-

ture correlating the stimulation of central DA receptors
to rat locomotor activity (Maj et al., 1972b; Buus Lassen,
1977), stereotyped behavior (Ernst, 1967; Anden et al.,
1967) and hypothermia (Kruk, 1972).

There is also evidence

showing that when DA antagonists are given to rats, catalepsy
results (Costall and Naylor, 1974a).

The ability of the

DA antagonists HAL, LEN, CPZ and TRZ to abolish the effects of APO as well as induce a state of catalepsy in the
present experiments is presumptive evidence that APO and
the DA antagonists used in this study exert their effects
via DA receptors.

This is in agreement with other findings

in rats that APO induces locomotor stimulation (Di Chiara
and Gessa, 1978; Anden et al., 1967; Iversen, 1975),
stereotypy (Ernst, 1967; Randrup and Munkvad, 1974) and
hypothermia (Barnett et al., 1972; Cox et al., 1978) and
that DA antagonists not only block locomotor stimulation,
stereotypic and hypothermic effects of APO (Buus Lassen,
1974; 1977; Di Chiara and Gessa, 1978; Fuxe and Sjoqvist,
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1972) but also induce a state of catalepsy in the rat
(Munkvad et al., 1968).
The neuroleptics selected for this study include compounds reported to possess similar antipsychotic properties
with differential incidences of EPS.

HAL and CPZ, which

are used as antipsychotic agents and are known to cause a
high incidence of EPS (Crane, 1967; Hanlon et al., 1965),
are referred to as typical neuroleptics.

LEN and TRZ,

which possess antipsychotic properties and non-typical
neuroleptic properties in animal models (Quock and Louie,
1977; Ljungberg and Ungerstedt, 1978), give a low degree
of EPS (Harris, 1975; Carranza and Toro, 1974), and are referred to as atypical neuroleptics.
This study shows that the central DA antagonists employed produce common pharmacological actions.

They all

inhibit APO-induced locomotor activity, stereotyped behavior and hypothermia as well as induce catalepsy.
are, however, differences in potency.

There

The data obtained

from this study indicate that in the pharmacological parameters measured, HAL is the most potent followed in order
by LEN, CPZ and TRZ.

An exception was observed in the body

temperature studies where TRZ was slightly more potent than
CPZ in blocking APO-induced hypothermia.
TRZ was qualitatively different from HAL, LEN and
CPZ in that the APO-induced locomotion was blocked at doses
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that did not reduce the APO-induced stereotyped behavior or
induce catalepsy (Table II, III, IV).

The ED

50

for TRZ's

ability to block APO-induced locomotor activity was sufficient to completely block APO-induced hypothermia
(Table IX).

LEN, HAL and CPZ were able to block APO-induced

locomotor activity at doses that blocked APO-induced stereotyped behavior and hypothermia but did not induce catalepsy
(Table II, III, IV, V).

The cataleptogenic ED

50

of all four

DA-antagonists is higher than the anti-apomorphine dose
(Table VI, VII, VIII, IX).
The results in the present study on the antagonisms
of the APO-induced effects agree with previous studies since
TRZ has been shown not to antagonize APO-induced stereotyped behavior or induce catalepsy at doses that blocked
APO-induced locomotor activity, while HAL and CPZ have been
shown to antagonize APO-induced locomotor activity and stereotypy at equipotent doses (Buus Lassen, 1977; Ljungberg and
Ungerstedt, 1978; Niemegeers and Janssen, 1979).

Although

pretreatment with LEN was observed to reduce the thermotropic and locomotor actions of APO in rabbits and rats
while leaving the intensity of APO-induced compulsive
gnawing unaltered (Quock and Louie, 1977), this study
clearly shows that LEN antagonized-APO-induced stereotypy
behavior and hypothermia at doses that block APO-induced
locomotor activity.

This also seems to be inconsistent

with clinical observations in which LEN was reported to
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produce a lower-than-expected, based on neuroleptic potency,
incidence of EPS (Harris, 1975).
The determination of systemic ED

50

values and time-

activity relationships for these neuroleptics in the
pharmacological parameters previously mentioned will not
necessarily show selectivity of the agents for DA receptors
in particular regions of the CNS.

However, if the activity

changes resulting from structurally different neuroleptics
were compared to one another by means of regression analysis,
gross differences in selectivity for DA receptors could be
demonstrated quantitatively.

A plot of the log molar ED

50
of HAL, LEN, CPZ and TRZ in one pharmacological parameter
versus the log mole ED

50

values of these neuroleptics in a

second pharmacological parameter should yield a regression
line with a high correlation coefficient if the compounds
are binding to receptor sites with identical 3-dimensional
structure (topography) and chemoselectivity.

Conversely,

if the DA receptors influencing the different pharmacological
parameters are topographically dissimilar, then the plot of
the activity in one DA function versus the activity of a
second DA function would not yield a linear correlation.
This non-parallel change in activity indicates that the
drugs being tested are binding to non-identical receptor
sites (isoreceptors) in causing their various pharmacological
effects.

Assuming that isoreceptors do exist, if the com-

pounds being tested have isoreceptor selectivity then the
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regression correlation plot showing the activity of a particular series of compounds in a pharmacological parameter
governed by a population of DA receptors from one brain
region may not produce a linear correlation with the
activity of the same series of compounds in a pharmacological parameter gove.rned by a population of DA receptors
from either the same or another brain region.

By the same

rationale, the extent of activity changes in one pharmacological parameter by that same series of compounds would
be expected to correlate with those compounds' pharmacological findings believed to be associated with the same
population of DA receptors.
According to this mode of analysis, the activity
changes reuslting from the different neuroleptics parallel
each other for the various parameters measured.

The plot

of the pharmacological activity in one DA function versus
the activity in a second DA function yields a linear correlation in all cases with correlation coefficients ranging
from 0.92 to 0.99.

The parallel changes evident in the

analysis of each pair of biological functions indicate
that the compounds are binding to identical receptor
sites or are not selective among isoreceptors.
On closer examination of the regression analysis plots,
only the log molar ED

of TRZ on its ability to block APO50
induced hypothermia compared to the log molar ED
of TRZ
50
on its ability to block APO-induced stereotyped behavior and
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locomotor activity and its ability to induce catalepsy deviates from the regression line when comparing the log
molar ED

50

of HAL, LEN and CPZ in one pharmacological

parameter to each of the others (Figure 23, 24, 25, 26,
27, 28).

As it appears that HAL, LEN, CPZ and TRZ exert

their effects via the DA receptor in the pharmacological
parameters tested, the peculiarity of TRZ in the regression analysis

plots and its ability to block APO-induced

hypothermia at doses that do not reduce APO-induced locomotor activity or stereotyped behavior or induce a state
of catalepsy may be due to four different possibilities.
First, the metabolism of TRZ may result in a more
active metabolite in the area of the hypothalamic thermoregulatory center or a more inactive form in other parts
of the brain known to contain dopaminergic neuronal
tracts such as the limbic forebrain or the nigrostriatal
system.

As shown by the studies of Zehnder et al. (1962),

the metabolism of TRZ is mainly by demethylation of the
nitrogen atom of the side chain to produce northioridazine.
The next metabolic, step is oxidation of the two sulphur
atoms to sulphones and sulphoxides.

Northioridazine is

therapeutically active and the side-chain sulphone derivative of TRZ is used as a neuroleptic agent (Hopf and Eckert,
1971).

As far as hard knowledge of the metabolic fate of

neuroleptic drugs is concerned, there is no evidence to
support a differential metabolism of TRZ or any of the other
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neuroleptics tested in the brain to account for the results
obtained with TRZ in this study.
Second, the apparent selectivity of neuroleptic action
may result from differential distribution of TRZ in the CNS.
The distribution pattern for TRZ was determined by Hopf and
Eckert (1971) in the rat brain using radio-active
minutes after i.v. injection, the activity of

14

TRZ.

Five

C-thioridazine

was found to be particularly high in the limbic system whereas the archicortical hippocampus and the hypothalamus contained little labelled substance.

After periods of 1 to 24

hours the activity was situated mainly in the forebrain,

the

hippocampus, neocortex and thalamus whereas a gradual decline in activity was seen in all other brain regions.

Since

the hypothalamus, which generally has a very permeable
blood-brain barrier, showed low activity, the effect of the
barrier cannot be very great.

The distribution pattern thus

cannot be accounted for in simple terms, and is apparently
determined by a number of different factors.

Although the

pattern of distribution for TRZ reveals a low content in
the hypothalamus, one cannot rule out the possibility that
this structure may have a high enough concentration of TRZ
to evoke a pharmacological response.

In order to eliminate

drug distribution problems, the neuroleptic agents employed
in this study could be administered in microquantities
directly into CNS regions where various DA neuronal systems
are known to be located.

This procedure would localize
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the antagonists in the anatomical regions of the brain where
DA neuronal functions vary.
Third, a number of studies have been carried out to
measure the antimuscarinic potencies of various neuroleptics.
Binding studies using specific radiolabelled ligands for
muscarinic receptors indicate that TRZ belongs to the class
of drugs endowed with potent antimuscarinic properties
(Miller and Hiley, 1975; Laduron and Ley sen, 1978).
Similar results were obtained with in vivo studies using
mydriatic activity in mice and in vitro studies using
guinea-pig trachea in which TRZ was rated as a potent antimuscarinic agent, more so than CPZ or HAL (Pearl et al., 1976)
There is considerable evidence to support the concept
that there exists a modulatory relationship between cholinergic
and dopaminergic neuronal systems in the CNS.

The majority

of the literature concerning the neuroanatomical basis of
the interaction between these two neurotransmitter systems
involve the extrapyramidal system (Kelly and Miller, 1975;
Muller and Seeman, 1974; Morpurgo, 1962).

It has been sug-

gested that the antimuscarinic property of TRZ may be responsible at least in part, for its lack of production of
EPS when used clinically (Kelly and Miller, 1975).
In the present study, TRZ's failure to block APOinduced effects and induce catalepsy at doses which blocked
APO-induced hypothermia in the rat may be the result of its
antimuscarinic properties.

In addition to TRZ's

119

antidopaminergic property, its antimuscarinic action may
alleviate the dopaminergic,effects of APO in the hypothalamic thermoregulatory center further enhancing TRZ's
ability to block APO-induced hypothermia.

There is evi-

dence to support the hypothesis that APO-induced hypothermia involves a cholinergic link (Glick and Marsanico,
1974).

It was reported that APO produced dose-dependent

hypothermic effects in mice which were antagonized by
scopolamine.

However, Cox and Lee (l977a) were unable to

block APO-induced hypothermia with scopolamine at doses

l

-I

which were highly effective in antagonizing oxytremorineinduced hypothermia in rats and mice.

Since the exact

nature of the interaction between the cholinergic and
dopaminergic systems in thermoregulation is as yet unclear,
TRZ's antimuscarinic property does not provide the evidence
to account for the results obtained with TRZ in this study.
Fourth, there is the possibility of multiple receptors
for DA in the CNS of the rat.

Since TRZ appears to be more

selective for DA recpetors of the hypothalamic thermoregulatory center versus the DA receptors of the corpus
striatum or the limbic system, the DA receptors governing
body temperature regulation in the hypothalamus are presumed to be topographically and chemoselectively dissimilar to DA receptros in the striatal and limbic systems.
In recent years, the available data indicates the
existence of numerous subtypes of DA receptors.

The clinical
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observations of Klawans (1973) provided some of the first
available evidence that supported the existence of two
types of DA receptors.

The concept of a balance between

the DA exitatory and inhibitory mechanisms was developed
by Cools and Van Rossum (1976).

Their critical review

developed into a comprehensive account of two distinct DA
receptor types in striatal and mesolimbic brain areas.
In behavioral studies classical and atypical neuroleptics differentially antagonized APO-induced stereotypy
and locomotion supporting the hypothesis that there exist
different DA receptor types in striatal and mesolimbic areas
of the brain (Ljungberg and Ungerstedt, 1978).
--- J

Differential

HVA accumulation in these areas of the brain of rats pretreated with classical or atypical neuroleptics further
support this multiple receptor hypothesis (Bartholini, 1976;
Uzan et al., 1978).
Various studies present evidence that the presynaptic
neuron itself might contain DA autoreceptors (Christiansen
and Squires, 1974; Aghajanian, 1977) suggesitng pre- and
postsynaptic DA receptor types.

Radiolabelled ligands have

been used in studies which have employed brain lesion techniques in attempts to locate DA agonist/antagonist binding
sites presenting further evidence for the existence of preand postsynaptic DA receptors (Nagy -et -al., 1978; Lee -et -al.,
1978).
The study of drug action on the DA-sensitive adenylate

121

cyclase system has provided a criteria for designation of
multiple categories of DA receptors.

The proposed DA

receptors linked to, or independent of, the DA-sensitive
adenylate cyclase has been referred to as D-1 and D-2
respectively (Kebabian and Calne, 1979).

Other studies

with kainic acid lesions and ablations of the cerebral
cortex have provided further evidence to distinguish at
least two types of DA receptors in the neostriatum, those
linked to adenylate cyclase and those independent of the
enzyme located on axon terminals of corticostriatal fibers
(Schwarcz et al., l978b).

More recent data indicate that

the bovine anterior pituitary contains two distinct DA
receptors, one which is not associated with adenylate
cyclase and which controls prolactin release, the other
adenylate cyclase linked and regulated by GTP with, as
of yet, unknown physiological function (Sibley and Creese,
1979; Caron et al., 1978).
In view of the present findings,

it appears that TRZ

may be blocking a subclass of DA receptors present in the
preoptic anterior hypothalamus which are topographically and
chemoselectively dissimilar to those DA receptors governing stereotyped behavior, locomotor stimulation and the
induction of catalepsy in rats.
To further elucidate this possibility, it would be of
interest to determine whether or not other atypical neuroleptics such as clozapine and sulpiride might share TRZ's
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differential action upon preoptic anterior hypothalamic DA
receptors.

To determine whether selective antagonism of

these receptors is a result of actual differences in DA
receptor types and not simply differential distribution
within the CNS, central microinjection techniques would be
used in further studies.
Expanding the number of pharmacological tests to inelude measuring HVA accumulation in the corpus striatum,
hypothalamus and limbic forebrain following the administration of neuroleptic drugs may show differential turnover
of DA.

For example, neuroleptics that produce a selective

blockade of DA receptor types found predominantly in the

- 1

j

hypothalamus will hence enhance hypothalamic HVA levels
with little effect elsewhere in the brain.
The establishment of a DA receptor binding procedure
would allow for the direct assessment of the extent of
receptor binding of the neuroleptic agents employed in this
study in tissues isolated from the striatum, hypothalamus
and limbic forebrain.

The data from these binding studies

as well as the turnover studies would be subjected to regression analysis along with our pharmacological findings.
Finally, it would be most useful to expand this study
to incorporate data from clinical studies using the same
neuroleptic agents used in the pharmacological, biochemical
and binding studies.

A clinical profile of a neuroleptic
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with respect to its antipsychotic potency and incidence of
EPS would indeed make for a more complete study when this
data is treated along with the other data using regression analysis.

CONCLUSIONS
The present study in male Wistar rats was designed to
support the hypothesis of multiple receptor types for DA
in mammalian CNS tissue.

Four neuroleptic compounds were

subjected to a series of whole animal screening procedures
in an effort to demonstrate gross differences in selectivity for DA receptors.
The results of the present study indicate that APOinduced locomotor activity, stereotyped behavior and
hypothermia are produced in rats through central stimulation of DA receptors.

The ability of the neuroleptics

(HAL, LEN, CPZ and TRZ) to abolish the effects of APO as
well as induce a state of catalepsy in these experiments
is evidence

that APO and these DA antagonists exert their

effect via DA receptors.
This study shows that LEN was able to antagonize APOinduced stereotyped behavior and hypothermia at doses that
blocked APO-induced locomotor activity.

This finding is

inconsistent with clinical observations in which LEN was
reported to produce lower-than-expected EPS (Harris, 1975).
The results of this study were analyzed by the method
of regression analysis and revealed parallel activity changes
124
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from HAL, LEN, CPZ and TRZ for each of the four pharmacological parameters measured.

Only the log molar ED

of TRZ
50
on its ability to block APO-induced hypothermia compared
to the log mole ED

values of TRZ on its ability to block
50
APO-induced stereotyped behavior and locomotor activity and
its ability to induce catalepsy deviates from the regression
line when comparing the log mole ED

values of HAL, LEN
50
and CPZ in one pharmacological parameter to each of the
others.
It may be concluded f:hom this investigation that

Cl)

differential metabolism and/or (ii) differential dis-

tribution of TRZ may be responsible for its differential
activity at the hypothalamic thermoregulatory center; (iii)
that TRZ's antimuscarinic action was responsible for enhancing its ability to block APO-induced hypothermia;
and (iv) TRZ may be more selective for a population of
DA receptors present in the preoptic anterior hypothalamus
which are topographically dissimilar to DA receptors elsewhere in the CNS.
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